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ABSTRACT 
      Lung cancer is the leading cause of cancer death in the world. Across all stages 
and all types of lung cancer, the overall 5-year survival is less than 15%. Non-small cell 
lung cancer (NSCLC) accounts for approximately 80% of lung cancer cases. Tumors 
from approximately 10-15% of NSCLC patients in the U.S. harbor epidermal growth 
factor receptor (EGFR) kinase domain mutation. 
      Exon 19 deletion mutation and exon 21 substitution mutations are the two most 
prevalent mutations in EGFR tyrosine kinase domain. These kinase domain mutations 
lock EGFR in a constitutively active conformation, leading to hyper-activation of pro-
survival and anti-apoptotic signaling pathways in NSCLC. In addition, NSCLC harboring 
the EGFR kinase domain mutations exhibits a typical oncogene addiction model, where 
the cells are exquisitely dependent on mutant EGFR for cell survival and proliferation. In 
this model, successful inhibition of the oncogene results in oncogene shock; which 
promotes cell cycle arrest and/or cell death. Structurally, EGFR with exon 19 deletion 
and exon 21 substitution mutations shows higher affinity to small molecule-reversible 
EGFR tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib than ATP. 
Consequently, the reversible EGFR TKIs preferentially inhibit EGFR tyrosine kinase 
activity to promote oncogene shock in the subset of NSCLC with EGFR kinase domain 
activating mutations. In the clinic, patients with the EGFR kinase domain mutations 
initially respond well to the EGFR inhibitors; however, acquired drug resistance will 
mainly emerge after 6-18 months of treatment.    
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      Besides the well-established EGFR TKI resistant mechanisms such as the EGFR 
T790M secondary mutation and MET gene amplification, 30% of resistant mechanisms 
are still unknown. Systematic genetic and histological analyses of tumor biopsies from 
patients show that about half of the patients present an evidence of epithelial to 
mesenchymal transition (EMT). EMT is characterized by the loss of epithelial cell 
junction marker E-Cadherin and gain of mesenchymal cell marker such as N-Cadherin 
and Vimentin. EMT is associated with many cellular changes, however, the molecular 
mechanisms by which mesenchymal-like cells attenuate their dependency on EGFR with 
kinase domain mutations are still unknown. We hypothesize that the induction of 
mesenchymal transition in NSCLC cells harboring EGFR kinase domain mutation 
promotes aberrant upregulation of bypass receptor tyrosine kinases (RTKs) or other 
oncogenic drivers to replace the oncogenic mutant EGFR. 
      While this hypothesis was being tested, several groups have demonstrated by 
Zhang’s group that receptor tyrosine kinase AXL is upregulated in EGFR-mutant NSCLC 
cell lines with acquired resistance to erlotinib with mesenchymal features. It has been 
shown that AXL activates downstream pathways to bypass the mutant EGFR 
downstream signaling in NSCLC cells with the mesenchymal phenotype. Despite this 
finding, we failed to demonstrate that AXL is the oncogenic driver in our mesenchymal 
NSCLC models. Instead, we observed overexpression of chemokine receptor CXCR7 in 
vitro and NSCLC models of acquired resistance to EGFR TKI with mesenchymal 
phenotype. Consequently, we hypothesized that CXCR7 is an oncogenic driver in EGFR 
mutant NSCLC cells with acquired resistance to EGFR TKI to offset the activation of 
downstream signaling by mutant EGFR. To test this hypothesis, we ectopically 
  
 
 
overexpressed V5 tagged CXCR7 in EGFR mutant NSCLC cells. Our studies 
demonstrate that ectopically overexpressing CXCR7 in EGFR mutant NSCLC cells is 
sufficient to promote EGFR TKI resistance and EMT. Furthermore, we demonstrated 
that EGFR TKI resistance induced by ectopic CXCR7 overexpression in mutant EGFR 
NSCLC cells is reversible. We also demonstrated that CXCR7 knockdown not only 
restored sensitivity to EGFR TKI but also partially reversed mesenchymal phenotype to 
epithelial phenotype. In summary, our data suggested CXCR7 as a promising 
therapeutic target for preventing or overcoming EGFR TKI resistance in a subset of 
EGFR mutant NSCLC patients. 
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CHAPTER ONE 
INTRODUCTION 
Overview of lung cancer 
      Lung cancer is the leading cause of cancer death in the United States (1). About 
1.35 million new patients are diagnosed with lung cancer every year (1) and the 5-year-
survival rate is less than 15% (1). Lung cancer originates in the tissue of lungs or cells 
lining the bronchi and cancer cells continually accumulate mutations which promote 
aberrant cell growth and proliferation. 
      Lung cancers are typically divided into two main categories: small cell lung cancer 
(SCLC) and non-small cell lung cancer (NSCLC). About 85% to 90% of lung cancers are 
NSCLC and 10 percent of cases are SCLC (2). Some patients are diagnosed with a 
combined SCLC/NSCLC cancer as well (2). Based on whether the cancer is local or has 
spread from the lungs to the lymph nodes or other organs, lung cancer has been defined 
as different stages (3). In Stage I, the cancer is located only in the lungs and has not 
spread to any lymph nodes. In stage II, the cancer is in the lung and nearby lymph 
nodes. In the stage III, cancer is found in the lung and in the lymph nodes in the middle 
of the chest, also described as locally advanced disease. Stage IV is the most advanced 
stage of lung cancer, and is also described as advanced disease. This is when the 
cancer has spread to both lungs, to fluid in the area around the lungs, or metastasized to 
another part of the body. The early symptoms like coughing and fatigue are not easily 
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noticed, even 7-10% of patients with lung cancer are asymptomatic, lung cancer has a 
poor prognosis and most people with lung cancer are not diagnosed when the disease is 
well advanced. 
After the initial diagnosis of NSCLC, it is necessary to determine the patients’ stages 
accurately in order to make the right therapeutic decision (3). Treatment of lung cancer 
mainly involves surgery, chemotherapy, radiation therapy and more recently targeted 
therapy-alone, or in combination (4). Surgery to remove the tumor is the most potentially 
curative therapeutic options for the NSCLC in the stage I and early stage II periods. 
Surgery in combination with chemotherapy and radiation could also provide great 
efficacy than surgery alone and could reduce the chance of recurrence. Because most 
lung cancer cannot be completely cured by the current therapy, appropriate palliative 
care is also a very important part in the lung cancer treatment (5). 
      One of the most exciting developments in lung cancer therapy is the introduction 
of targeted therapies. Targeted therapies are designed specifically to attack the 
abnormal molecules responsible for the specific tumor so that they are considered to be 
more effective and have fewer side effects as compared to traditional chemotherapies 
(6). The identification of oncogenic drivers that are known to play essential roles in 
cancer growth and survival in NSCLC cells is necessary for the efficacy of targeted 
therapies. Patients who have advanced lung cancer with certain molecular biomarkers 
may benefit from targeted drug alone or in combination with chemotherapy (7). Among 
these, epidermal growth factor (EGFR) kinase domain mutations in NSCLC strongly 
predict the improved response rate and progression-free survival by EGFR inhibition (6).  
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EGFR kinase domain mutant NSCLC 
    EGFR is a trans-membrane cell surface receptor tyrosine kinase (8). It is a member 
of ErbB family of receptors (8). ErbB family is composed of four structurally related 
receptor tyrosine kinases: ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 
(HER4). These receptors consist of an extracellular ligand-binding domain, a trans-
membrane lipophilic domain and an intracellular tyrosine kinase domain. EGFR is 
activated by binding of its ligands including epidermal growth factor (EGF) and 
transforming growth factor-α (TGF- α) (8). Upon binding by its ligands, EGFR undergoes 
conformational changes which promote homo-dimerization with EGFR or hetero-
dimerization with other ERBB family members such as ErbB3. EGFR dimerization 
stimulates the auto-phosphorylation of its tyrosine residues in the intracellular domain 
through transferring γ-phosphates from adenosine triphosphate (ATP) (9). This 
phosphorylations lead to: 1) increased catalytic efficiency and furthering phosphorylation 
of other downstream substrates; 2) phosphorylated tyrosine carboxyl-terminals 
constitute docking sites and recruit other downstream signaling proteins containing SRC 
homology 2 (SH2), protein tyrosine-binding domains (PTB), or other phosphor-tyrosine-
binding domains (10, 11) EGFR together with its downstream substrates form signaling 
complexes, and subsequently initiate downstream signaling cascades controlling 
multiple cellular processes, including phosphatidylinositol 3-kinase (PI3K)/AKT pathway, 
Ras/Raf/mitogen-activated protein kinase pathway (MAPK) pathway, which contribute to 
cell survival and proliferation (12, 13).  
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     In 2004, two groups from the Dana-Farber/ Harvard Cancer Center identified 
somatic mutations in the tyrosine kinase (TK) domain of EGFR in most NSCLC patients 
who respond well to a small molecule EGFR tyrosine kinase inhibitor (TKI) (14, 15). As 
EGFR TKI preferentially inhibits mutant EGFR, the efficacy of EGFR TKI is profound in 
NSCLC tumors that express mutant EGFR but not in normal cells that express wild type 
EGFR. EGFR kinase domain mutations are present in approximately 30-35 percent of 
cases in East Asian NSCLC patients and 10 percent of cases in Caucasian NSCLC 
patients, especially non-smoking young Asian female patients (16, 17), and are more 
associated with adenocarcinomas with bronchioalveolar features (18). The most 
prevalent mutations in the EGFR tyrosine kinase domain are located within EGFR exon 
18-21, which are around the ATP-binding pocket of enzyme (18) . 45 percent of the 
cases are exon 19 deletion, amino-acids between residues 747-750 of EGFR 
polypeptide. L858R point substitution mutation in exon 21 also comprises approximately 
40-45 percent of EGFR mutations. Nucleotide substitution in exon 18 or exon 20 
insertion individually accounts for 5 percent of EGFR mutations (18). Kinase domain 
mutations increase the kinase activity of EGFR, leading to hyper-activation of PI3K and 
MAPK signaling pathways and consequently confer oncogenic effects (14, 18). 
Therefore, cancer cells, which harbor EGFR kinase domain mutations become addicted 
to EGFR signaling for their survival and proliferation. In addition, mutant EGFR changes 
its kinase domain structure, decreases its affinity to ATP and increases its affinity for 
small molecule EGFR TKI such as gefitinib (Iressa) and erlotinib (Tarceva) (15). EGFR 
TKI competes with ATP for binding to the catalytic binding site (19) . In the clinic, NSCLC 
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patients harboring EGFR kinase domain mutations are associated with increased 
sensitivity to EGFR TKI. One of the major effects of EGFR TKI in sensitive EGFR-mutant 
NSCLC cells is the induction of intrinsic apoptosis pathways (20, 21). PI3K and MAPK 
signaling pathways have been shown to cooperate to promote cell survival and 
proliferation on NSCLC (22). EGFR TKI inhibits both PI3K and MAPK pathways and kills 
EGFR addicted NSCLC. MAPK inhibition after EGFR TKI treatment leads to rapidly 
increased activity of proapoptotic protein BIM in EGFR mutant NSCLC by increasing the 
production and dephosphorylation of BIM (20, 21). PI3K inhibition after gefitinib 
treatment leads to downregulation of anti-apoptotic protein myeloid leukemia cell 
differentiation 1 (MCL1) (23). The upregulation of BIM cooperates with the 
downregulation of MCL1 to promote cell death. Despite the initial response to EGFR 
TKI, the development of resistance inevitably occurs after 6-18 months treatment (24). 
Resistance to EGFR-target therapy 
      Primary resistance: Most EGFR kinase domain mutations confer sensitivity to 
EGFR TKI; however, some EGFR kinase domain mutations predict the primary 
resistance to EGFR TKI. There are insertions or duplications mutations that occur in 
exon 20 in EGFR gene, resulting in amino acid insertion between D770 and N771 or 
substitution in amino acid position 771, render the receptor 100-fold less sensitive to 
gefitinib or erlotinib as compared to tumors harboring the exon 21 substitution mutations 
or exon 19 deletions in EGFR (25, 26). Although in most cases, exon 20 T790M 
mutations are associated with acquired resistance to EGFR TKI, presence of T790M 
also links to the primary resistant mechanism (27). 
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      NSCLC tumor harboring EGFR mutation could be insensitive to EGFR TKI 
because of the presence of other genetic alterations that co-occur with EGFR mutations. 
EGFR downstream signaling pathways, PI3K and MAPK, are critical for cell survival and 
proliferation in EGFR mutant NSCLC (22). Tumor cells sensitive to EGFR TKI are 
characterized by remarkable down-regulation of AKT phosphorylation (28, 29). 
Consequently, activating mutation in phosphaticylinositol-4,5-biphophate 3-kinase, 
catalytic subunit alpha (PIK3CA) is found to rescue the cells from sensitivity to EGFR 
TKI (30). Also, loss of phosphatase and tensin homologue (PTEN) expression, which 
indirectly regulate the activation of AKT, correlates with decreased sensitivity of EGFR 
mutant NSCLC to EGFR TKI (31). Insulin-like growth factor receptor 1 (IGFR1), has 
been implicated as a potential resistant mechanism through crosstalk with EGFR to 
continually activate PI3K signaling pathway in EGFR overexpressed glioblastoma cells 
(32). Recently, Bivona et al. identified the hyperactivation of NFkB pathway as a new 
mechanism of primary resistance to gefitinib or erlotinib (33) . This group observed 18 
genes that are involved in NFkB signaling were directly or indirectly amplified in EGFR 
TKI resistant EGFR mutant NSCLC cells. Activation of NF-kB through overexpression of 
c-FLIP or IKK, or silencing of IkB, rescued EGFR-mutant lung tumor cells from EGFR 
TKI treatment. On the contrary, inhibition of FAS and several components of the NF-kB 
pathway specifically enhanced EGFR TKI induced cell death in EGFR-mutant lung 
cancer (33). 
It has been increasingly clear that cancer cells that express the canonical 
mesenchymal markers have intrinsic resistance to EGFR TKI (34, 35). Independent 
7 
 
 
 
research groups have processed gene expression and proteomic profiles in an attempt 
to identify epithelial and mesenchymal cell biomarkers that related to sensitivity to EGFR 
TKI (34, 35). They found that the cell lines which were sensitive to the EGFR inhibition 
expressed the canonical epithelial markers and displayed the typical epithelial 
phenotype. On the contrary, cell lines which were resistant to EGFR inhibition expressed 
the canonical mesenchymal cell markers and displayed the typical mesenchymal 
phenotype (34, 35). In addition, restoration of the canonical epithelial cell marker E-
Cadherin increases the sensitivity to EGFR TKI in NSCLC cell lines (36). 
      Acquired Resistance: Although NSCLC patients harboring EGFR mutations 
respond well to EGFR TKI, the drug resistance mainly develops within 6-18 months of 
treatment (24). The emergence of acquired resistance to EGFR TKIs greatly limits the 
efficacy of EGFR TKI to prolong patient survival (18). In order to overcome the acquired 
EGFR TKI resistance, it becomes more important to study the molecular and cellular 
mechanisms underlying the acquired EGFR TKI resistance. 
       About 50 percent of the acquired resistant cases are attributed to the emergence 
of the second-site gatekeeper mutation in EGFR exon 20, which is a change of a 
threonine to a methionine in amino acid position 790 (T790M) (37). The mechanism by 
which the T790M mutation confers resistance to gefitinib and erlotinib has been 
demonstrated that T790M secondary mutation restores the affinity of EGFR to ATP 
again, as a result, restore enzymatic activity of EGFR (38). T790M secondary mutation 
reduces the therapeutic effect of gefitinib or erlotinib to the patients. 
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       MET, which is a transmembrane receptor tyrosine kinase encoded by an 
oncogene, has been observed to be amplified in up to 20 percent patients who develop 
EGFR TKI resistance after several month treatments (39). MET amplification contributes 
to EGFR TKI resistance through a mechanism called ‘receptor kinase switch’ and it can 
occur independently or can coexist with EGFR T790M mutation among EGFR TKI 
secondary resistance (40). MET dimerization and activation can occur in either ligand-
dependent or ligand-independent way. MET ligand was identified as hepatocyte growth 
factor (HGF), also named as scatter factor (SF) (39, 41). Published studies have verified 
that EGFR mutant NSCLC cells activate the PI3K pathway through dimerization of 
EGFR with ERBB3 and down-regulation of PI3K signaling is the marker of sensitivity to 
gefitinib or erlotinib (42, 43). MET amplification replaces the function of EGFR sustaining 
the activation of PI3K signaling by coupling to ERBB3 in gefitinib resistant EGFR mutant 
NSCLC cells (39). In addition, the MET ligand HGF has been reported to induce gefitinib 
resistance by independently activating PI3K signaling pathway (41). Different from the 
MET receptor amplification that promotes EGFR TKI resistance in EGFR mutant NSCLC 
cells through coupling to ERBB3 and activating ERBB3/PI3K axis, HGF induces drug 
resistance through activating MET/PI3K signaling axis (41). MET amplification was also 
observed, although rare, in EGFR mutant NSCLC patients before gefitinib treatment and 
associated with EGFR TKI resistance (44). 
      Among all EGFR TKI resistant mechanisms in EGFR mutant NSCLC, EGFR 
T790M secondary mutation and MET amplification mutations account for 60-65 percent 
of all cases. Tumors from remaining EGFR TKI resistant cases neither harbor secondary 
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T790M mutation nor MET amplification. Sequist et al. performed a comprehensive 
genetic and histological analysis of 37 NSCLC patients before and after EGFR TKI 
treatment (45). All patients either had EGFR exon 19 deletion mutations or exon 21 
L858R substitution mutations and initially respond to EGFR TKI, but subsequently 
developed drug resistance. Besides T790M secondary mutations and MET amplification, 
5 percent of patients develop mutations in PIK3CA (45). Sequist et al. also found 
phenotypic transformation from NSCLC to SCLC leads to EGFR TKI resistance in 14 
percent of patients with acquired resistance (45). The study reported that about 30% of 
the resistant mechanisms remain elusive. Among these unknown resistant mechanisms, 
about half of the NSCLC patients present evidence of epithelial to mesenchymal 
transition (EMT).  
Overview of EMT 
      EMT is an evolutionarily conserved process by which cells undergo morphological 
changes from the epithelial polarized cell-cell adhesion phenotype to a more migratory 
invasive and fibroblast-like mesenchymal phenotype (46). The molecular markers of 
EMT are associated with transcriptional reprogramming such as decreased expression 
of proteins involved in cell junction such as E-Cadherin, and increased expression of 
mesenchymal cell markers such as Vimentin and N-Cadherin (47). EMT was first 
recognized as a feature of embryogenesis (46). Epithelial and mesenchymal cells are 
different not only in phenotype but also in functions. During embryonic development, 
differentiated epithelial cells could lose their cell-cell junction and basolateral polarity and 
undergo morphogenetic changes to migratory invasive mesenchymal cells, referred to 
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as EMT. After reaching specific sites, mesenchymal cells are recruited and differentiate 
to epithelial tissue and organs through mesenchymal to epithelial transition (46). 
      Reduced E-Cadherin expression disrupts the cell-cell adherence junction and 
polarized cell shape, so that the loss of E-Cadherin is considered to be an essential 
biomarker of EMT (48, 49). E-Cadherin loss has been implicated with activation of β-
catenin and its nuclear translocation (50, 51). β-catenin is a critical intracellular protein 
associated with the E-Cadherin cytoplasmic tail and has been much reported to play an 
important role in the induction of EMT (51) . The loss of E-Cadherin result in the 
dephosphorylating and activating of β-catenin molecule that is otherwise phosphorylated 
and targeted for ubiquitylation and degradation. Activated β–catenin forms a nuclear-
localized transcriptional complex with other transcription factors, including Snail, ZEB1, 
and Twist, and promotes complex gene expression changes that contribute to the EMT 
process (51). 
      Several extracellular signals such as transforming growth factor-β (TGF-β) 
signaling (52), Wnt signaling (53), Notch pathway (53), receptor tyrosine kinases (53, 54) 
also trigger EMT by complex signaling networks. The consequences of these signaling 
are upregulation of transcription factors, including Snail, Slug, and Twist which have high 
affinity for the E-box elements in the E-Cadherin promoter and inhibit E-Cadherin 
expression (55).  
EMT and acquired EGFR TKI resistance 
      Much effort has been focused on understanding how EMT regulates the 
progression of NSCLC cells to be more invasive and metastatic; however, relatively less 
11 
 
 
 
effort has been made on elucidating how EMT promotes resistance to EGFR target-
therapies in NSCLC harboring mutant EGFR.  
      EMT has been shown to promote acquired resistant mechanism to EGFR TKI in 
the NSCLC cell line models harboring EGFR kinase domain mutations. EMT was 
observed in about 15 percent cases among post-gefitinib treatment tumors (45). Suda et 
al. reported that chronic exposure of EGFR mutant HCC4006 cells to increasing 
concentration of erlotinib induced epithelial to mesenchymal transition and confer the 
cells resistance to erlotinib (56). Additionally, restoration of canonical epithelial cell 
marker E-Cadherin using histone deacetylase inhibitor MS-275 restored the sensitivity of 
erlotinib in the HCC4006 cells with acquired resistance to erlotinib (56). EMT is 
associated with many cellular changes; however, the molecular mechanisms by which 
mesenchymal-like cells attenuate their dependency on EGFR for survival and 
proliferation are still unknown. One explanation is that EMT promotes the cells to acquire 
alternative pathways so that the survival of the cells is independent of EGFR signaling. 
As a result, cells with a mesenchymal phenotype are resistant to EGFR TKI (57). It has 
been shown that the cancer cells can shift the cellular dependence in the response of 
EGFR TKI treatment (42, 58). PI3K and MAPK signaling pathways are critical for the 
survival and proliferation in NSCLC cells with mesenchymal phenotype (34), therefore, 
the molecular determinants of activation of PI3K and MAPK pathways which promote 
cellular resistance to EGFR TKI induced apoptosis have been actively investigated. 
Involvement of AXL in EGFR TKI resistance in EGFR mutant NSCLC with EMT 
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      AXL is a tyrosine phosphorylated 140kDa protein which belongs to a member of 
Tyro3-Axl-Mer (TAM) receptor tyrosine kinase (RTK) subfamily (59) and was first 
isolated from patients with chronic myelogenous leukemia (CML) and chronic myelo-
proliferative disorder (60). Like all RTKs, AXL consists of an extracellular domain, a 
transmembrane domain and a cytoplasmic domain with kinase activity. The extracellular 
domain of AXL is composed of a combination of two immunoglobin-like (Ig) motifs and 
dual fibronectin type III (FN III) repeats (59). AXL transduces signals by binding to its 
specific ligands. Protein S and vitamin K-dependent protein growth arrest–specific 6 
(Gas6) are ligands for AXL, whereas only the Gas6 is confirmed as high affinity to AXL 
(61, 62). Like other RTKs, conventional activation of the receptor involves ligand binding 
to the extracellular domain. Ligand binding induces receptor dimerization and trans-
phosphorylates tyrosine residues in the cytoplasmic kinase domain (63). Phosphorylated 
tyrosine recruits other downstream signaling proteins binding to it through their phospho 
tyrosine-binding SH2 domain. The primary signaling downstream of AXL appears to be 
the PI3K and MAPK signaling pathways (64, 65). AXL dimerization and activation has 
been shown to occur in a ligand-independent manner- homophilic binding of extracellular 
domains between neighboring cells (66) and AXL overexpression (67). AXL activation 
and signaling have been linked to multiple cellular responses, including cell survival, 
proliferation, adhesion and cytokine production, as well as immune-regulatory (68).  
      The role of AXL in cancer biology has attracted attention. AXL has been implicated 
to be upregulated in variety of cancers including breast (69), gastric (70), prostate (71), 
lung (72). Overexpression of AXL has been reported as relative to increased tumor 
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growth rate, metastasis and poorer prognosis (72, 73). Recently, AXL has also been 
considered as a potential candidate for overcoming EGFR TKI resistance in EGFR 
mutant NSCLC cells through activation of PI3K and MAPK signaling by its 
overexpression or binding to its ligand GAS6 (74). AXL activation enables the cells to 
bypass the mutant EGFR signaling in a manner similar to the resistant mechanism 
mediated by MET amplification in mutant EGFR NSCLC. The phenomenon is termed as 
‘receptor tyrosine kinase switch’. Zhang et al. group has developed tumor model with 
acquired resistance to erlotinib in vitro using HCC827 NSCLC cell line with EGFR kinase 
domain exon 19 deletion mutation and in vivo model with HCC827-derived xenograft 
tumors (74). They found that AXL was highly overexpressed in the EGFR TKI resistant 
groups with mesenchymal phenotype, as compared to the vehicle-treated tumors. 
Inhibition of AXL by chemical or genetic methods restored erlotinib sensitivity in HCC827 
cells. They validated the finding in matched pre- and post-EGFR TKI treatment clinical 
specimens from 35 NSCLC patients with either exon 19 deletion or exon 21 point 
mutation of EGFR and concluded that AXL or GAS6 overexpression was associated with 
resistance to EGFR TKI (74). Furthermore, AXL promotes the expression of anti-
apoptotic BCL-2 family members and to inhibit the expression of pro-apoptotic BAD 
family proteins which are responsible for the resistance of target therapy (75).  
      In addition to its role as an oncogenic driver in the EGFR TKI resistant NSCLC 
cells, AXL is also associated with the process of EMT (76). In pancreatic cancer, 
Koorastra et al. observed that AXL expression is necessary to maintain EMT 
transcription factors expression, such as Snail, Slug and Twist (73). AXL is also 
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demonstrated as a downstream effector of the EMT program in many tumor types since 
the activation of EMT program promotes the upregulation of AXL and downstream 
signaling (53, 76, 77). A recent published paper from Asiedu group revealed a novel 
function of AXL in acting upstream to induce EMT in normal epithelial breast cancer cells 
(78). Moreover, it has been shown that downregulation of AXL promotes mesenchymal 
to epithelial transition in mesenchymal breast cells (78). 
      Byers et al. performed a comprehensive gene expression signature analysis of 76-
gene EMT signatures and demonstrated that epithelial and mesenchymal phenotypes 
determine EGFR TKI sensitivity in NSCLC harboring mutant EGFR (79). Among the 
genes which are upregulated in the mesenchymal groups, they found high level of AXL. 
AXL overexpression in mesenchymal like NSCLC cells was further confirmed by 
proteomics approach and reverse-phase protein array (RPPA). The author then 
validated the correlations between EMT and poor erlotinib response. NSCLC patients 
were subjected to Biomarker-integrated Approaches of Targeted Therapy for Lung 
Cancer Elimination (BATTLE-1) trail. Patients with an EMT signature including increased 
level of AXL and its ligand GAS6 predicted poor clinical outcome to erlotinib as compare 
to the patients without EMT signature. Furthermore, in vitro, they found AXL inhibition 
together with EGFR inhibition had a striking synergistic effect compare to EGFR 
inhibition alone in AXL overexpressing mesenchymal NSCLC cells.  
      Collectively, these data suggest that AXL / GAS6 and its downstream signaling 
pathways serve as a potential mechanism associated with EGFR TKI resistance in 
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EGFR mutant NSCLC with mesenchymal phenotype. Detection and targeted therapy to 
AXL may be a new avenue to circumvent this resistance. 
Chemokine receptor CXCR7 and its potential role in acquired EGFR TKI resistance 
with epithelial to mesenchymal transition 
      C-X-C chemokine receptor type 7 (CXCR-7), formerly known as RDC1, was first 
cloned from a dog thyroid cloned DNA (cDNA) library (80). CXCR7 is a member of the 
G-protein-coupled receptor family and has the canonical structural features of GPCRs 
with a seven-transmembrane helices connected by extracellular and intracellular loops. 
It is known that chemokine ligands CXCL12 (or stromal-derived growth factor-1, SDF1) 
and CXCL11 (or IFN-inducible T cell α-chemoattractant, I-TAC) transmit their signals by 
binding to the receptor (81, 82). Expression of CXCR7 plays a role in cardiac 
development as well as with tumor growth and progression (82, 83). 
      Unlike classical G-protein coupled receptors which are initiated by binding with 
heterotrimeric G proteins, CXCR7 is activated by association with β-arrestin (84). In the 
absence of ligand, CXCR7 constitutively interacts with Gαi, but does not activate them. 
Ligand binding to CXCR7 recruits G protein receptor kinase (GRK) which in turn 
phosphorylates and activates the receptor. Phosphorylated receptor then increases its 
affinity to β-arrestin and results in activation of MAPK and PI3K signaling pathways (84). 
The process of CXCR7 activation is a model of ligand initiated, G-protein-independent, 
β-arrestin-dependent signaling pathways (84-86). 
       Signal transduction initiated by CXCR7 is controlled at the membrane by the 
process of CXCR7 trafficking. The level of receptor expression at the cell membrane 
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directly affects the magnitude of the cellular response initiated by the ligand binding (87). 
Apart from the β-arrestin-dependent manner, reversible ubiquitination plays an essential 
role in the regulatory mechanism of CXCR7 internalization (87). Ubiqutination is a post-
translational process that results in the covalent bond of the small protein ubiqutin to a 
lysine in the modified protein with profound consequences for endocytic cycles of the 
receptor (88). This modification of ubiquitination is mediated by three distinct enzymes. 
Ubiquitin is processed by an E1-activating enzyme, forming a thioester bond with 
ubiquitin that is required for transfer to E2-conjugating enzymes, and E3 ubiquitin ligases 
facilitate the covalent attachment of ubiquitin to substrate proteins (88). A recent study 
suggests that CXCR7 is constitutively ubiquitinated and such ubiquitination is important 
in modification of receptor trafficking (87). CXCR7 ubiquitination is necessary for cell 
surface delivery of the receptor. The absence of this ubiquitination leads to a 
constitutively internalized receptor. Upon ligand stimulation, CXCR7 phosphorylation at 
serine/threonine in the C-terminus promotes β-arrestin recruitment. β-arrestin interacts 
with a de-ubiquitinating enzyme (DUB) causing CXCR7 de-ubiquitination and 
endocytosis. On the contrary, disassociation of β-arrestin and interacting proteins would 
render the receptor to undergo ubiquitination and ubiquitinated receptors are recycled 
back to the cell surface (87). 
      Accumulating evidence suggests that CXCR7 plays an essential role in the 
survival, proliferation, metastasis of tumor cell lines including breast, lung, glioma (82, 
89, 90). Thus, CXCR7 has attracted more and more attention in the cancer research 
field as a potential pharmacological target for cancer therapy. Higher CXCR7 expression 
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is observed in neoplastically transformed cells as compared to their non-transformed 
control group supporting the notion that CXCR7 is important during tumorogensis (82). It 
is also verified that CXCR7 signaling increased growth rate of sarcoma cells in nude 
mice (91). In addition, higher expression of CXCR7 in NSCLC and prostate cancer cells 
show a positive correlation in tumor metastatic potential and development (92, 93). It is 
reported that CXCR7-transduced murine human breast or lung cancer cell lines grow 
larger tumors in immunodeficient mice, wherase decreasing the expression level of 
CXCR7 using siRNA shrink the lung tumor size in the vivo study (89). The roles of 
CXCR7 in different types of tumor cells are not entirely consistent. For example, Burns 
et al. demonstrated that CXCR7 was remarkably overexpressed in breast cancer cell 
line MDA-MB-435a and it was required to inhibit apoptosis rather than increasing 
proliferation in the cells (82) , whereas Meijer et al. reported CXCR7 played an important 
role in cell proliferation in mouse colon and pancreatic cancer cells (94). 
      In addition, the involvement of CXCR7 in neoangiogensis and formation of the 
tumor vasculature has been postulated since higher expression of CXCR7 has been 
found in breast cancer-related blood vessels compared to the blood vessel in normal 
breast tissue (89). CXCR7 overexpression has also been observed in blood vessels of 
other clinical carcinoma biopsy samples such as lung, kidney, prostate (95, 96). 
Moreover, CXCR7 overexpression in prostate cancer correlates with the increased 
production of vascular endothelial growth factor (VEGF) and IL-8 which have been 
shown to be important factors involved in the development of tumor blood supply in the 
progression of solid tumor (95). 
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       Of note, recent studies proposed that high expression of CXCR7 correlates with 
tumor metastatic potentials. One prostate cancer study from Wang J et al. suggested 
that high expression of CXCR7 predicted highly aggressive metastasis (95). They found 
CXCR7 expression regulated CD44 antigen (CD44) as well as cadherin 11 (CDH11) 
levels. CD44 was found to play a critical role for metastatic behavior of tumor cells 
including pancreatic cancer (97), prostate cancer (98), head and neck cancer (99). 
Similarly, expression of CDH11 was also regulated by CXCR7. CDH11 was identified to 
be expressed in mesenchymal cells and in a subset of highly invasive cell lines and 
aggressive breast carcinomas (100). In the study, they observed that expression level of 
CXCR7 also regulated TGF-β expression. TGF-β is reported to induce mesenchymal 
transition in epithelial cells (101), and exposure to TGF-β is associated with reduced 
sensitivity to gefitinib in NSCLC (102). Another research group reported that higher 
expression of CXCR7 was found in early and metastatic recurrence in pathological stage 
I NSCLC (92). Moreover, the level of CXCR7 is found to be significantly higher in the 
highly metastatic hepatocellular carcinoma cells and inhibition of CXCR7 by siRNA 
remarkably reduced tumor proliferation and metastatic invasion (103). 
      In conclusion, all the evidence demonstrate the importance of CXCR7 in cell 
signaling pathways and cancer metastatic behavior and also raise the exciting possibility 
that CXCR7 potentially facilitates EGFR TKI resistance in EGFR mutant NSCLC with 
mesenchymal phenotype.
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CHAPTER TWO 
MATERIALS AND METHODS 
Cell lines: HCC827, HCC4006, NCI-H1975 cell lines were obtained from the American 
Type Culture Collection (ATCC) and were maintained in RPMI-1640 growth media (Life 
Technologies, Carlsbad, CA) supplemented with 5% fetal bovine serum (FBS) (Life 
Technologies, Carlsbad, CA), 1X anti-biotic/anti-mycotic agent (AB/AM) (Life 
Technologies, Carlsbad, CA). HCC4006, NCI-H1975 cell lines were maintained in RPMI-
1640 supplemented with 10% FBS, 1X AB/AM. 293LTV cells were obtained from Cell 
Biolabs (San Diego, CA) and cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Life Technologies, Carlsbad, CA) supplemented with 10% FBS and 1X AB/AM. Cells 
were cultured at 37°C in a humidified incubator of 5% CO2. All clones generated using 
HCC827 cells used in the experiments were authenticated by short tandem repeat (STR) 
profiling. 
Lentiviral package and production: For virus packaging, the 2.5X 105 293LTV cells 
were transfected with 4 μg cDNA cloned in pEXP304-blasticidin vectors or shRNA 
sequence cloned in pLKO.1-puromycin vectors together with 4 μg Δ8.2 and 0.6 μg 
VSVG lentiviral packaging vectors using 14 μl TransIT-LT1 transfection reagent (MIRUS, 
Madison, WI). Transfection mixture was prepared in the proper volume of optiMEM (Life 
Technologies, Carlsbad, CA) to make up the total volume to 250 μl. After incubated for 
20 minutes added to the cells suspended in RPMI-1640 supplemented with 10% FBS 
without AB/AM and the cells were incubated in the transfection mix for 24 hours. 24 
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hours post transfection, culture media was replaced with virus production media that is 
made of DMEM supplement with 10% FBS, 0.2 g/ml BSA, 1X AB/AM. The supernatant 
was harvested 72 and 96 hours post-transfection and the viral supernatant was filtered 
using Nalgene Syringe Filter 0.45μm (Thermo Scientific, Hanover Park, IL) and stored in 
4°C or -80°C until use.  
Target gene knockdown using lentiviral pLKO.1shRNA vector: Bacterial stock of 
short hairpin RNA (shRNA) clones in pLKO.1 designed by The RNA Consortium 
(MIT/Harvard Broad Institute, Cambridge, MA) were purchased from Open Biosystem 
(Pittsburgh, PA) or Sigma (St. Louis, MO). In the shRNA experiments, lentiviral encoding 
shRNA was packaged in 293LTV cells as described above. Target NSCLC cells were 
transduced at least twice with viral supernatants. Cells containing the target expression 
were selected with 5 µg/ml puromycin after infection. 
Generation of HCC827 cells stably overexpressing shRNA against Non-Target/ 
EGFR/ CDH1: HCC827 cells with stably expressing shRNA against non-target (NT), 
EGFR and CDH1 cells were generated by transducing exponentially growing HCC827 
cells with lentivirus coding for shRNA against NT, EGFR and CDH1, respectively. 
Following infection, the cells were subjected to the antibiotic selection to ensure the 
expression of shRNA against target. The cells were cultured in RPMI-1640 
supplemented with 5% FBS, 1X AB/AM and 5 µg/ml puromycin. Mass culture was 
established for HCC827 stably overexpressing shRNA against NT sequence. Western 
blot was performed using antibody against EGFR or CDH1 to ensure that there is no 
deletion of EGFR or CDH1 in the mass culture. For the generation of HCC827 cells 
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stably expressing shRNA against EGFR or CDH1, single clones were established 
following puromycin selection. Single clones were screened for knockdown efficiency 
and clone with best EGFR or CDH1 knockdown were used for experiments.  
Generation of HCC827 or NCI-H1975 cells stably overexpressing GFP or LacZ or 
CXCR7: Exponentially growing HCC827 cells or NCI-1975 cells were seeded on 60x 15 
mm dishes at the density of 6x105 cells and allowed to adhere to the plate overnight. The 
cells were then transduced for overnight with lentivirus coding for GFP or LacZ, CXCR7 
tagged with V5 tag. This process was repeated three times to ensure that the cells 
express the genes. HCC827 or NCI-H1975 cells were then subjected to antibiotic 
selection with 20 µg/ml blasticidin. Following the selection, mass culture was established 
and the expression of LacZ-V5 and CXCR7-V5 were confirmed with Western blot using 
antibodies against V5 tag. Ectopic CXCR7-V5 expression is also confirmed with Western 
blot using antibodies against CXCR7. The expression of GFP was confirmed using 
EVOS-XL fluorescent microscope.  
Lentiviral knockdown of CXCR7 in HCC827 cells ectopically overexpressing 
CXCR7: HCC827 cells ectopically overexpressing GFP or CXCR7-V5 were grown in 
RPMI-1640 supplemented with 5% FBS, 1X AB/AM and 20 µg/ml blasticidin and were 
transduced with lentivirus coding for NT shRNA or CXCR7 shRNA. To ensure 
knockdown of the targets, the cells were transduced twice. The cells were then 
subjected to antibiotic selection with 20 µg/ml blasticidin and 5 µg/ml puromycin. Mass 
culture resistant to both blasticidin and puromycin were generated and knockdown 
efficiency was confirmed with Western blot using antibody against V5 or CXCR7. The 
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cells were maintained in RPMI-1640 supplemented with 5% FBS, 1X AB/AM, 20 µg/ml 
blasticidin and 5 µg/ml puromycin. 
Drugs: Gefitinib and XL-184 (ChemieTek, Indianapolis, IN) were prepared as a 10mM 
stock solution in dimethyl sulfoxide (DMSO) and stored in -20°C until use and used at 
concentrations ranging from 0.001 to 10 µM. 
Cell viability assay: Cells were seeded at a density ranging from 2000-3000 depending 
on cell lines per well on 96-well plates and allowed to adhere overnight in the 
appropriate growth media mentioned in the cell line section. Subsequently, cells were 
treated with increasing concentrations of drugs serially diluted in growth media for 72 
hours, and subjected to cell viability assay with Cell Counting Kit-8 (CCK-8) (Dojindo 
Molecular Technology, Inc., Rockville, Maryland). Samples were prepared in duplicates. 
After the incubation with CCK-8, plates were read on a microplate reader (Bio-Tek, 
Winooski, VT). The data were collected and analyzed by the graphpad prism version 
5.00 for Windows (GraphPad Software, La Jolla, CA). The results were expressed as 
mean viable cells relatively to RPMI-1640 alone (considered as 100% viability) ± SD. 
Western blot: The cells were cultured in the tissue culture plates (BD Falcon, San Jose, 
CA), allowed to attach overnight. To assess cell signaling, cells were incubated with the 
indicated drug concentration or control DMSO and incubated for 24 or 48 hours. The 
cells were washed twice with ice-cold 1X modified DPBS with Calcium and Magnesium 
and whole-cell lysates were prepared in the lysis buffer containing 20 mM Tris-HCl 
(PH7.5), 15 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4, 1µg/ml leupeptin (Cell 
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Signaling Technology, Danvers, MA) supplemented with Halt protease and phosphatase 
single-use inhibitor cocktail (Pierce, Rockford, IL). To detect CXCR7, we use lysis buffer 
containing 62.5 mM Tris-HCL (pH 6.8), 2% SDS, 10% sucrose, supplemented with halt 
protease and phosphatase single-use inhibitor cocktail (Pierce, Rockford, IL). Protein 
concentrations were determined using Pierce bicinchoninic acid (BCA) protein assay kit 
(Pierce, Rockford, IL) and equivalent amount of protein were subjected to mini-protean 
TGX 4-20% gradient gels (Bio-Rad, Hercules, CA) and blot with different antibodies 
(Table 1.) Blot detection was done by ECL Western Blot Detection Reagents 
(PerkinElmer, Waltham, MA). After Western blot, films were developed and scanned. 
Loading were corrected with ImageJ software (NIH Image, Bethesda, MD). 
Table 1. Antibody list 
 
 
 
Phospho-RTK array analysis: Proteome Profiler human phospho-RTK antibody array 
(R&D Systems, Minneapolis, MN) was used according to the manufacturer’s instructions 
to measure the relative level of tyrosine phosphorylation of 42 distinct receptor tyrosine 
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kinases (RTKs). Cells were seeded in 10x20mm dishes at a density of 2.0x106 and the 
cells were allowed to adhere to the plates overnight. Cells were then treated with either 
control DMSO or 1 µM gefitinib for 24 hours. The cells lysates were prepared by 
solubilizing the cells at 1x107 cells/ ml in RTK array specific lysis buffer (R&D Systems, 
Minneapolis, MN). 100 µg of fresh protein lysates were incubated with array membranes 
overnight at 4°C. The membranes were then incubated with anti-phosphotyrosine-HRP 
antibody for 2 hours at room temperature to detect tyrosine phosphorylated RTKs. 
Western blot was done by ECL Western Blotting Detection Reagents (PerkinElmer, 
Waltham, MA). Then the membrane was exposed to X-ray film to detect activated 
receptors. 
siRNA transfection: Silencer validated small interfering RNAs (siRNAs) for AXL, 
CXCR7 and control NT were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). 2.0x105 cells were seeded into 6-well plates and allowed to attach overnight. 
Concentration of 3.5 μl of 10 μM siRNA and 6 µl of TransIT- siQUEST transfection 
reagent (MIRUS, Madison, WI) were each mixed with 250 µl of optiMEM medium. 
Solution was incubated for 20 minutes in the room temperature before added to the 
cells. siRNA mediated knockdown efficiency was measured by Western blot after 96 
hours of transfection. 
Apoptosis AnnexinV Assay: 3x105 cells were seeded in duplicates in the 6-well tissue 
culture plates, allowed attaching to the plate overnight. To assess drug effect to the cell 
apoptosis, Annexin V staining was proceeding after 48 hours drug treatment. Annexin V 
binding buffer (Cell Signaling Technology, Danvers, MA) was used at the concentration 
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range from 1x105 to 1x106 cells/ml after washing with ice-cold growth media. 96 µl of cell 
suspension was transferred to a 5 ml flow tube, stained with AnnexinV/FITC (Cell 
Signaling Technology, Danvers, MA) and PI (Cell Signaling Technology, Danvers, MA) 
and incubated on ice in the dark for 10 minutes. The stained cell suspension was then 
subjected to the Fluorescently Activated Cell Sorting (FACS) analysis using BD canto II 
machine (BD Biosciences, San Jose, CA). Results were analyzed by using Flowjo 
software (Tree Star Inc. Ashland, OR). 
qRT-PCR: To validate changes in gene expression identified in gene expression 
profiling, RT-PCR was performed to quantify the amount of target mRNA. Total RNA 
was isolated using RNeasy Mini Kit (Qiagen, Germantown, MA) according to the 
manufacturer’s instructions. The quantity of RNA and purity were determined using 
NanoDrop ND-1000 (Thermo Scientific, Hanover Park, IL) and Qubit 2.0 Flurometer 
(Invitrogen, Carlsbad, CA). cDNA was synthesized from 500 ng total RNA using high 
capacity cDNA reverse transcription kit (Applied Biosystems, Forster City, CA). For qRT-
PCR analysis of RNA expression, the RT- PCR was performed in a 20 µl reaction 
volume containing TaqMan Universal master mix (Applied Biosystems, Forster City, CA). 
Cycling conditions were set as 50°C 2 minutes- 95°C 10 minutes- 95°C 15 minutes- 
60°C 1min. RT-qPCR was performed and the values were obtained of the threshold 
cycle for the CXCR7 and normalized using the housekeeping gene GusB. 
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Table 2. CXCR7 Primers list 
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CHAPTER THREE 
RESULTS 
EGFR or E-Cadherin depletion by lentiviral shRNA in HCC827 cells induces 
epithelial to mesenchymal transition. HCC827 NSCLC cells overexpress EGFR with 
the exon 19 deletion mutation and are exquisitely sensitive to EGFR TKI (14). Usually, 
acquired resistance to EGFR TKI is studied by exposing HCC827 cells to increasing 
doses of EGFR TKI for up to 6 months in tissue culture system (37). The problem of this 
approach is that off-target effects of EGFR TKI might contribute to the development of 
acquired resistance to EGFR TKI. To eliminate the possibility of off-target effects, Dr. 
Shimamura stably knocked down EGFR using lentiviral shRNA against EGFR in  
HCC827 cells (HCC827 shEGFR) and acquired resistant clones with mesenchymal 
phenotype were isolated (acquired resistant clone with MET amplification was also 
observed, data not shown). Robert Weinberg and his colleagues have demonstrated that 
the depletion of E-Cadherin in breast epithelial cells is sufficient to promote 
mesenchymal transition (51). Motivated by this finding and to investigate if inducing a 
mesenchymal phenotype in HCC827 cells is sufficient to confer EGFR TKI resistance in 
HCC827 cells, HCC827 cells were transduced with lentivirus coding for shRNA against 
E-Cadherin (CDH1) and stable clones were isolated by Dr. Shimamura. HCC827 with 
constitutive E-Cadherin knockdown cells (HCC827 shCDH1) were irreversibly 
transitioned to the mesenchymal state. HCC827 cells transduced with lentiviral shRNA 
against non-target served as control (HCC827 shNT). We observed that canonical 
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epithelial cell marker E-Cadherin is significantly downregulated whereas canonical 
mesenchymal cell marker N-Cadherin is upregulated in HCC827 shEGFR and HCC827 
shCDH1 cells as compared to control HCC827 shNT cells (Figure 1B). 
Mesenchymal-like HCC827 cells with constitutive EGFR or E-Cadherin knockdown 
are resistant to EGFR tyrosine kinase inhibitor gefitinib. NSCLC cells that display 
mesenchymal phenotype are resistant to EGFR TKI (34, 48). To determine if HCC827 
cells with mesenchymal phenotype are resistance to EGFR TKI, HCC827 shNT, 
HCC827 shEGFR and HCC827 shCDH1 cells were subjected to cell viability assay with 
EGFR TKI- gefitinib for 72 hours. As shown in Figure 1A, epithelial HCC827 shNT cells 
are exquisitely sensitive to gefitinib with the IC50 0.008 µM, while mesenchymal 
HCC827 shEGFR and HCC827 shCDH1 cells were resistant to gefitinib with the IC50 
1.35 µM and 0.24 µM respectively. The IC50 of HCC827 shEGFR and HCC827 shCDH1 
cells to gefitinib increase more than 30 fold. In addition, we challenged the cells with 
DMSO or 1 µM gefitinib for 48 hours. The cells were lysed at the end of 48 hour 
treatment and lysates were subjected to Western blot with the antibodies indicated 
(Figure 1B and1C). Exposure of HCC827 shEGFR to gefitinib did not promote PARP 
cleavage and exposure of HCC827 shCDH1 cells to gefitinib promoted resulted in 
decreased level of the PARP cleavage, which is a late apoptosis marker (104), as 
compared to the control HCC87 shNT cells (Figure 1B). EGFR downstream signaling 
pathways, PI3K and MAPK, are critical for cell survival and proliferation in EGFR mutant 
NSCLC (22) and cells sensitive to EGFR TKI are characterized with remarkable down-
regulation of phosphorylated AKT (28, 29). Gefitinib treatment effectively inhibited 
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activity of EGFR (Figure 1C) in HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 
cells. We observed remarkably decreased phosphorylation of AKT, ERK in HCC827 
shNT cells (Figure 1C) which indicated that gefitinb treatment effectively depleted the 
downstream signaling in control cells. In contrast, phosphorylating AKT and ERK were 
maintained in HCC827 shEGFR cells after gefitinib treatment. Although gefitinib 
effectively inhibit the phosphorylating ERK, we observed the maintained level of 
phosphorylating AKT in HCC827 shCDH1 cells (Figure 1C). Our observation indicates 
that in mesenchymal like HCC827 cells, when the activity of EGFR is completely 
inhibited, cells sustained their downstream signaling pathway. 
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Figure 1. Mesenchymal-like HCC827 cells with constitutive EGFR knockdown or E-
Cadherin knockdown are resistant to EGFR TKI gefitinib. A, Exponentially growing 
HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells were treated with 
indicated concentration of gefitinib for 72 hours in duplicate and cell viability were 
accessed using Cell Counting Kit-8. The viability of each sample was normalized to that 
of DMSO-treated cells. Points, average of normalized values for experiments in 
duplicates; error bars, SD. B, Exponentially growing HCC827 shNT, HCC827 shEGFR 
and HCC827 shCDH1 cells were treated with 1µM control DMSO (-) or gefitinib (+) for 
48hrs and lysates were subjected to Western blot with indicated antibodies. HCC827 
shEGFR and HCC827 shCDH1 cells are mesenchymal phenotype with downregulation 
of E-Cadherin and upregulation of N-Cadherin expression and resistant to gefitinib 
treatment as evidenced by no or significantly reduced PARP cleavage. C, Exponentially 
growing HCC827 shNT, HCC827sh EGFR and HCC827 shCDH1 cells were treated with 
1µM control DMSO (-) or gefitinib (+) for 48hrs and lysates were subjected to Western 
blot with indicated antibodies. Gefitinib treatment promoted depletion of phospho-EGFR, 
phospho-AKT and phospho-ERK in HCC827 shNT cells. In contrast, mesenchymal 
HCC827 shEGFR and HCC827 shCDH1 cells are resistant to gefitinib and EGFR 
inhibition failed to completely inhibit phospho-AKT.  
 
Part I: Tyrosine receptor kinase AXL 
EGFR TKI resistant mesenchymal like HCC827 shEGFR and HCC827 shCDH1 cells 
are insensitive to AXL inhibition and AXL inhibition does not restore their gefitinib 
sensitivity. Recently, published studies indicate that upregulation of receptor tyrosine 
kinase AXL replaced the function of EGFR and sustained PI3K signaling pathway in 
EGFR TKI resistant NSCLC cells with mesenchymal phenotype when the activity of 
EGFR is completely inhibited (74, 79). In order to quickly determine if the survival of 
mesenchymal like HCC827 cells are dependent on AXL activation, we treated the cells 
with an inhibitor of AXL alone or in combination with EGFR inhibition and determined 
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percent control viability of the cells after 72 hours of drug treatment. Of note, there was 
no potent and selective AXL inhibitor at the time when the study was carried out. XL-184 
is a MET inhibitor which also inhibits AXL receptor with low concentration (7 nM) (105). 
Extremely high concentration of XL-184 was required to compromised the cell viability of 
HCC827 shNT, HCC827 shEGFR or HCC827 shCDH1 cells. In line with the previous 
observation, HCC827 shEGFR and HCC827 shCDH1 cells increase their resistance to 
gefitinib more than 17 fold with the IC50 2.4 µM and 0.14 µM, respectively. In contrast, 
HCC827 shNT cells were sensitive to the gefitinib treatment with the IC50 0.008 µM. In 
addition, XL184 did not restore gefitinib sensitivity in HCC827 shEGFR and HCC827 
shCDH1 cells (Figure 2). 
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Figure 2. AXL inhibition does not restore gefitinib sensitivity in EGFR TKI resistant 
mesenchymal-like HCC827 cells with constitutive EGFR knockdown or E-Cadherin 
knockdown. Exponentially growing HCC827 shNT, HCC827 shEGFR and HCC827 
shCDH1 cells were treated with indicated concentrations of gefitinib, XL-184 or 
combination of gefitinib and XL-184at ratio 1:1 for 72 hours in duplicate and cell viability 
were accessed using Cell Counting Kit-8. The viability of each cell was normalized to 
that of DMSO-treated cell. Points, average of normalized values for experiments in 
duplicates; error bars, SD.  
 
None of the 42 receptor tyrosine kinases listed in the RTK array seem to be driver 
of EGFR TKI resistant HCC827 shEGFR and HCC827 shCDH1 cells with 
mesenchymal phenotype. The data from Figure 1C showed the persistence of 
phospho- AKT when the inhibition of EGFR activity was completed in the mesenchymal-
like HCC827 cells, and raised the possibility that AXL or any other potential receptor 
tyrosine kinase was activated to offset the function of EGFR. To address this possibility, 
we performed profiling of phospho-receptor tyrosine kinase (RTK) array in HCC827 
shNT, HCC827 shEGFR and HCC827 shCDH1 cells with or without EGFR TKI 
treatment. 42 receptor tyrosine kinases including AXL and other known receptors linked 
to drug resistance in EGFR mutant NSCLC were tested. EGFR TKI treatment completely 
inhibited phosphorylation of EGFR and the analysis did not identify the activation of any 
RTK in mesenchymal-like HCC827 cells (Figure 3).  
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Figure 3. Analysis using RTK array demonstrates no RTKs are activated in 
mesenchymal-like EGFR TKIs resistant HCC827 cells upon gefitinib treatment. 
Lysates from HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with 
either DMSO or 1µM gefitinib for 24 hours were subjected to profiling of active RTKs-
using RTK array that detects 42 phosphorylated RTKs. In each array, RTK is assayed in 
duplicates. The dark dots represent activated RTKs. Right figure are made by Dr. 
Shimamura. 
 
 
AXL is upregulated in EGFR TKI resistant HCC827 shEGFR and HCC827 shCDH1 
cells with mesenchymal phenotype; however its activity is dependent on the 
activity of EGFR. Considering the limited sensitivity of RTK array, we confirmed 
expression and activation levels of AXL in HCC827 shEGFR and HCC827 shCDH1 cells 
treated with or without gefitinib by Western blot. We observed higher levels of AXL in 
HCC827 shEGFR and HCC827 shCDH1 cells. However, gefitinib reduced AXL 
phosphorylation (Figure 4), suggesting that AXL might be activated by EGFR-mediated 
trans-phosphorylation and AXL activity was dependent on the activation of EGFR. This 
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makes AXL less likely confer resistance to EGFR TKI treatment in mesenchymal-like 
HCC827 cells. 
 
 
 
 
 
Figure 4. EGFR inactivation downregulates AXL phosphorylation in mesenchymal-
like HCC827 cells with constitutive EGFR or E-Cadherin knockdown. Exponentially 
growing HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells were treated with 
DMSO or 1µM gefitinib for 48hrs and lysates were subjected to Western blot with 
indicated antibodies. Note that AXL is overexpressed and activated in HCC827 shEGFR 
and HCC827 shCDH1 cells; however, the phosphorylation of AXL is decreased upon 
treatment of HCC827 shEGFR and HCC827 shCDH1 cells with gefitinib. Expression of 
AXL/p-AXL indicated as 138kDa 
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AXL depletion neither induces cell apoptosis nor resensitizes HCC827 shEGFR or 
HCC827 shCDH1 cells to gefitinib. To further explore the role of AXL in acquired 
EGFR TKI resistance in HCC827 shEGFR and HCC827 shCDH1 cells and to avoid off-
target effect of XL-184, we transfected HCC827 shNT, HCC827 shEGFR and HCC827 
shCDH1 cells with siRNA coding for non-target or AXL and following either treated the 
cells with DMSO or gefitinib. In line with what we observed before, gefitinib induced the 
cell apoptosis in control HCC827 shNT cells with increased PARP cleavage. However, 
AXL depletion alone or in combination with gefitnib did not promote cell apoptosis in 
HCC827 shEGFR or HCC827 shCDH1 cells as evidenced by no PARP cleavage (Figure 
5). 
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Figure 5. AXL depletion alone or in combination with EGFR TKI do not induce 
apoptosis in mesenchymal-like EGFR TKI resistant HCC827 cells with constitutive 
EGFR or E-Cadherin knockdown. HCC827 shNT, HCC827 shEGFR and HCC827 
shCDH1 cells were transfected with control siRNA (-) or siRNA targeting AXL (+). 
Transfected cells were maintained in growth medium supplemented with 5% FBS. 
48hours post-transfection, cells were then treated with DMSO (-) or 500nM gefitinib (+) 
for additional 24 hours. Then the whole cell lysates were collected and subjected to 
Western blot. Neither depletion of AXL alone nor combination of AXL depletion and 
EGFR inhibition promotes PARP cleavage in HCC827 shEGFR and HCC827 shCDH1 
cells. Expression of AXL/p-AXL indicated as 138kDa. 
 
 
Part II: Chemokine receptor CXCR7 
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CXCR7 is commonly upregulated in mesenchymal- like HCC827 cells. Since we 
eliminated the possibility of AXL as an oncogenic driver replacing the function of EGFR 
in mesenchymal like HCC827 cells, in order to elucidate other possible candidates that 
confer EGFR TKI resistance, Dr. Shimamura performed comparative marker selection 
(CMS) for mesenchymal like HCC827 cells and parental HCC827 cells. Genes which are 
exclusively upregulated more than 3-fold in mesenchymal like HCC827 cells but not 
HCC827 parental cells were captured (Figure 6). Of note, besides HCC827 shEGFR and 
HCC827 shCDH1 cells, our lab also generated mesenchymal like HCC827 cells by 
chronically exposing the cells to TGF-β which is a potent inducer of EMTin various 
epithelial cells (101). 49 genes are commonly upregulated in mesenchymal like HCC827 
cells as compared to parental HCC827 cells including chemokine receptor CXCR7. 
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Figure 6. 49 unique genes commonly upregulated in the mesenchymal-like 
HCC827 cells. Comparative marker selection (CMS) was performed to identify genes 
uniquely upregulated in each mesenchymal-like HCC827 cells. Genes upregulated more 
than 3 fold over control at 95% confidence interval was identified for each mesenchymal-
like cells. 49 unique genes were found commonly upregulated in HCC827 TGF-β, 
HCC827 shEGFR and HCC827 shCDH1 cells. Figure was provided by Dr. Shimamura. 
 
 
CXCR7 is overexpressed in HCC827 shCDH1 cells. In order to confirm the CXCR7 
expression level identified in gene expression profiling, we performed RT-PCR to 
quantify the amount of mRNA of CXCR7 in HCC827 shNT, HCC827 shEGFR and 
HCC827 shCDH1 cells. Total RNA was isolated and analyzed for CXCR7 transcript in 
HCC827 shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with DMSO or 
gefitinib. CXCR7 was significantly enhanced in EGFR TKI resistant mesenchymal like 
HCC827 shCDH1 cells as compared to the control HCC827 shNT cells. Acute gefitinib 
treatment increased the level of CXCR7 in all HCC827 shNT, HCC827 shEGFR and 
HCC827 shCDH1 cells (Figure 7A). CXCR7 overexpression in mesenchymal like 
HCC827 shCDH1 cells was also detected in Western blot with DMSO or gefitinib 
treatment (Figure 7B).  
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Figure 7. CXCR7 is overexpressed in HCC827 cells with constitutive E-Cadherin 
knockdown. A, Quantitative RT-PCR analysis of CXCR7 transcript induction in HCC827 
shNT, HCC827 shEGFR and HCC827 shCDH1 cells treated with DMSO or gefitinib for 
24 hours. Total mRNA was extracted from HCC827shNT, HCC827 shEGFR and 
HCC827 shCDH1 cells treated with DMSO or gefitinib. Each sample was amplified in 
duplicate for quantification of CXCR7 and GusB transcripts. Mean expression level of 
CXCR7 was analyzed by relative quantitation using ΔΔCt method and normalization to 
GusB. Each bar represents the relative quantity of mRNA in one sample. Error bars, SD. 
CXCR7 transcripts were abundantly expressed in HCC827 with constitutively E-
Cadherin knockdown. B, To confirm that increase in the expression of CXCR7 
transcripts leads to the overexpression of CXCR7 protein, exponentially growing cells 
were treated with DMSO or 1µM gefitinib for 24 hours and lysates were subjected to 
Western blot with indicated antibodies. CXCR7 in HCC827 cells with constitutive E-
Cadherin knockdown is higher compare to the HCC827 shNT cells. Expression of 
CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translational 
ubiqutination type) 
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Ectopic CXCR7-V5 overexpression in HCC827 NSCLC cells. To systematically 
assess the role of CXCR7 in EGFR TKI resistant NSCLC cells, we ectopically 
overexpressed CXCR7 tagged with V5 in HCC827 cells (Figure 8). 
 
 
 
 
Figure 8. CXCR7-V5 was ectopically overexpressed in HCC827 cells. HCC827 cells 
were transduced with lentivirus coding for V5 tagged CXCR7 (CXCR7-V5) expression 
vectors. HCC827 cells transduced with lentivirus coding for GFP expression vector were 
used as a control. Cell lysates were made from exponentially growing HCC827 GFP 
cells or HCC827 CXCR7-V5 cells and the lysates were subjected to Western blot with 
antibodies against CXCR7, V5 tag and control β-Actin. CXCR7 and V5 overexpression 
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are confirmed in the HCC827 CXCR7-V5 cells. Expression of CXCR7 protein indicated 
as 42 kDa (immature type) and 52 kDa (post-translational ubiqutination type) 
 
Ectopic CXCR7 overexpression in HCC827 cells promotes mesenchymal 
phenotype. Unexpectedly, we observed the mesenchymal-like morphological change 
after ectopic CXCR7-V5 overexpression in HCC827 cells. HCC827 CXCR7-V5 cells 
exhibited spindle, elongated and scattered mesenchymal-like morphology while the 
control HCC827 GFP exhibited cobblestone and patching morphology (Figure 9). Since 
cells that transition into a mesenchymal state undergo cell canonical markers change, 
we investigated the canonical epithelial and mesenchymal markers for HCC827 GFP 
and HCC827 CXCR7-V5 cells. In consistent with what we observed in morphological 
changes, we detected that canonical epithelial marker E-Cadherin was significantly 
downregulated while canonical mesenchymal marker vimentin was upregulated in 
HCC827 CXCR7-V5 as compared to HCC827 GFP cells (Figure 10). 
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Figure 9. Phenotype changes in HCC827 cells with ectopic overexpression of 
CXCR7-V5. Bright field microscopic images (10x magnification) demonstrates ectopic 
expression of CXCR7-V5 in HCC827 promotes elongated mesenchymal-like cell 
morphology. HCC827 GFP cells show epithelial morphology which are cobblestone and 
flattend wheras HCC827 CXCR7-V5 cells show mesenchymal-like morphology which 
are scattered and elongated. 
 
 
 
200 µm 200 µm 
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Figure 10. Ectopic CXCR7-V5 overexpression in HCC827 cells promotes induction 
of mesenchymal-like phenotype. Whole cell lysates were made from exponentially 
growing HCC827 GFP or HCC827 CXCR7-V5 cells. The whole cell lysates were 
subjected to Western blot using indicated antibodies. HCC827 CXCR7-V5 cells display 
mesenchymal-like transition demonstrated by E-Cadherin downregulation and Vimentin 
upregulation compared to HCC827 GFP cells. 
 
Ectopic CXCR7 overexpression in NCI-H1975 cells promotes mesenchymal 
transition. In order to investigate if ectopic CXCR7 expression is sufficient to promote 
epithelial to mesenchymal transition in other EGFR mutant NSCLC cells, we 
overexpressed CXCR7 in NCI-H1975 cells which express L858R/T790M EGFR kinase 
domain mutations and are sensitive to irreversible EGFR TKI. In consistent with what we 
observed in HCC827 cells, ectopic CXCR7 overexpression in NCI-H1975 cells 
significantly decreased the level of canonical epithelial marker E-Cadherin and 
upregulated the canonical mesenchymal marker N-Cadherin (Figure 10). In addition, in 
NCI-H1975 CXCR7-V5 cells, we observed upregulation of Twist and Snail which are 
important transcription factors to induce mesenchymal phenotype in cultured cells (106) 
(Figure 10).  
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Figure 11. Ectopic overexpression of CXCR7 promotes mesenchymal phenotype 
in NCI-H1975 cells. NCI-H1975 cells were transduced with lentivirus coding for LacZ or 
CXCR7-V5 expression vectors. Cell lysates of NCIH1975 LacZ and NCI-H1975 CXCR7-
V5 cells were collected and subjected to the Western blot with antibodies against 
CXCR7, V5 tag and canonical epithelial or mesenchymal cell markers. Expression of 
CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translational 
ubiqutination type). 
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Ectopic CXCR7 overexpression is sufficient to confer EGFR TKI resistance in 
HCC827 cells. Epithelial to mesenchymal transition has been reported to confer drug 
resistance in EGFR mutant NSCLC (45, 56). Moreover, we hypothesized that HCC827 
cells with ectopic CXCR7 overexpression attenuates their EGFR TKI sensitivity through 
‘receptor switch’. To determine whether HCC827 CXCR7-V5 cells with mesenchymal 
phenotype are resistant to EGFR TKI, HCC827, HCC827 GFP and HCC CXCR7-V5 
cells were subjected to cell viability assay with gefitinib for 72 hours. By comparing IC50, 
we observed that HCC827 CXCR7-V5 cells with mesenchymal phenotype were 14 times 
resistant to gefitinib treatment as compared to control HCC827. We quantified 
percentage apoptosis induced by gefitinib using Annexin V-FITC/PI double staining and 
flow cytometric analysis. Data shown in Figure 13 shows that gefitinib treatment induced 
apoptosis in 46% of control HCC827 LacZ cells. However, gefitinib treatment induced 
apoptosis increased about 1 % of HCC827 CXCR7-V5 cells that is in different from 
percent of apoptotic cells found in DMSO treated HCC827 CXCR7-V5 cells (3.42%). In 
Western blot, gefitinib treatment induced significant increase in PARP cleavage in 
control HCC827 GFP cells while same treatment failed to induce PARP cleavage in 
HCC827 CXCR7-V5 cells (Figure 14). In addition, exposure of HCC827 GFP to gefitinib 
resulted in significantly decreased level of phospho- AKT and phospho-ERK indicating 
that gefitinib inhibited the downstream signaling in control cells. However, exposure of 
HCC827 CXCR7-V5 to gefitinib resulted in decreased the level of phospho-ERK; 
however, the level of phospho-AKT was maintained (Figure 14).  
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Figure 12. Ectopic overexpression of CXCR7 attenuates the sensitivity of HCC827 
cells to EGFR TKI. Exponentially growing HCC827, HCC827 GFP, HCC827 CXCR7-V5 
cells were treated with indicated concentration of gefitinib for 72 hours in duplicates and 
cell viability was assessed using Cell Counting Kit-8. The viability of each cell line was 
normalized to that of DMSO-treated cell. Points, average of normalized values for 
experiment in duplicates; error bars, SD. The table list calculated IC50 values against 
gefitinib. 
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Figure 13. Assessment of apoptosis by Annexin V-FITC/ PI double staning 
demonstrates that gefitinib treatment does not compromise viability of cells 
ectopically expressing CXCR7-V5. Quantification of flow cytometric analysis using 
Annexin V-FITC and propidium iodide staining indicates that 48 hours of 1μM gefitinib 
treatment does not induce apoptosis in CXCR7 overexpressing HCC827 cells. getinib 
treatment induced almost10 fold more cell death in HCC827 LacZ cells (49.2% 
apoptosis) when compared with DMSO treated HCC827 LacZ cells(5.98%) while there 
was no change in percentage apoptosis in HCC827 CXCR7-V5 cells treated with 
(4.68%) or without ( 3.42%) gefitinib. Right columns indicates average of normalized 
percent Annexin positive cells for two independent experiments; error bars, SD. 
 
 
 
N=2 
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Figure 14. Geftinib treatment promotes significantly less PARP-cleavage in 
HCC827 cells with CXCR7-V5 overexpression than in HCC827 GFP control cells. 
HCC827 GFP and HCC827 CXCR7-V5 cells were treated with DMSO or indicated 
concentration of gefitinib for 24 hours. The cells were lysed and the lysates were 
subjected to Western blot using indicated antibodies. HCC827 GFP cells are sensitive to 
gefitinib treatment as evidenced by the PARP cleavage and significant depletion of 
phospho-AKT, phospho-ERK after gefitinib treatment. In contrast, exposure to gefitinib 
does not promote PARP cleavage in HCC827 CXCR7-V5 cells and PI3K signal persists 
despite the inhibition of EGFR as evidenced by phospho-AKT.   
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CXCR7 depletion restores gefitinib sensitivity in HCC827 CXCR7-V5 cells. Our 
observations with stable CXCR7 expression in HCC827 cells demonstrated that ectopic 
CXCR7 expression confers EGFR TKI resistance in EGFR mutant NSCLC (Figure 
12,13,14). To further confirm that CXCR7 is sufficient to confer resistance to EGFR TKI, 
we depleted CXCR7 from HCC827 CXCR7-V5 cells to see if CXCR7 depletion would 
resensitize the HCC827 CXCR7-V5 cells to gefitinib. We stably knocked down CXCR7 
using lentiviral shRNA against CXCR7 in HCC827 CXCR7-V5 cells. CXCR7 was 
effectively depleted by shCXCR7 in HCC827 CXCR7-V5 cells as indicated in Figure 
15A. Exposure of HCC827 CXCR7-V5 cells with CXCR7 knockdown to gefitinib restored 
the level of cell apoptosis marker- PARP cleavage while HCC827 CXCR7-V5 cells 
transduced with shRNA against NT maintained the low level of PARP cleavage after 
treated with gefitinib (Figure 15B). In addition, depletion of ectopic CXCR7 expression in 
HCC827 CXCR7-V5 cells resulted in diminishing phospho-AKT and phosph-ERK after 
gefitinib treatment which was the manner similar as HCC827 GFP cells treated with 
gefitinib. In line with the previous observation, HCC827 CXCR7-V5 cells transduced with 
shRNA against NT maintained PI3K and MAPK signaling after treated with gefitinib 
(Figure 15C). 
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Figure 15. EGFR TKI resistance in HCC827 cells by ectopic overexpression of 
CXCR7 is reversible. A, HCC827 GFP (GFP) cells stably expressing non-target shRNA 
(NT) were established and treated with DMSO (-) or 500nM gefitinib (+) for 48 hours. 
HCC827 CXCR7-V5 (CXCR7-V5) cells stably expressing non-target shRNA (NT) or two 
best shRNA sequence targeting CXCR7 (CXCR7-1 and CXCR7-2) were established and 
treated with 1µM DMSO (-) or gefitinib (+) for 48 hours. Whole cell lysate were prepared 
and the lysate were subjected to the Western blot using indicated antibodies. Expression 
of CXCR7 protein indicated as 42 kDa (immature type) and 52 kDa (post-translationally 
modified type). B, Using the same lysates, Western blots with indicated antibodies were 
performed to confirm inactivation of EGFR and PARP-cleavage by gefitinib treatment. 
Note PARP-cleavage was not observed in gefitinib treated CXCR7-V5 overexpressing 
cells (4th lane), whereas knockdown of CXCR7 in CXCR7-V5 overexpressing cells 
restored sensitivity to gefitinib as evidenced by PARP-cleavage (lanes 6 and 8). C, 
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Using the same lysates, Western blots with indicated antibodies were performed to 
access PI3K and MAPK pathway activities by interrogating AKT (S473) and ERK (T202/ 
Y204), respectively. Representational figure from two independent experiments shown. 
 
 
CXCR7 knockdown partially reverse mesenchymal HCC827 CXCR7-V5 to 
epithelial. We observed stable CXCR7 overexpression in epithelial HCC827 cells 
induced the mesenchymal-like transition in EGFR mutant NSCLC (Figure 9,10). EMT is 
reported to be a reversible process (48) and CXCR7 knockdown reversed gefitinib 
sensitivity in HCC827 CXCR7-V5 cells, therefore we next investigated if EMT induced by 
ectopic CXCR7 overexpression in EGFR mutant NSCLC is also reversible. Depletion of 
CXCR7 in HCC827 CXCR7-V5 cells did not induce an apparent phenotype change 
when observed under microscope (data not shown). When investigated with Western 
blot, we observed increased level of canonical epithelial cell marker, ZO1 and decreased 
expression of canonical mesenchymal marker, Vimentin. However, the expression of E-
Cadherin after CXCR7 knockdown did not change` (Figure 15). The results indicate that 
CXCR7 depletion partially reverses HCC827 CXCR7-V5 to epithelial phenotype. 
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Figure 16. Depletion of CXCR7 partially restores epithelial phenotype. HCC827 
GFP (GFP) cells and HCC827 CXCR7-V5 (CXCR7-V5) cells were transduced with 
lentiviruses coding for non-target sequence (NT) or two best shRNA sequence targeting 
CXCR7 (CXCR7-1 and CXCR7-2). Stable cell lines were established. Whole cell lysate 
were prepared and the lysates were subjected to the Western blot using indicated 
antibodies to interrogate canonical epithelial and mesenchymal markers. HSP90 serves 
as loading control.  
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CHAPTER FOUR 
DISCUSSION 
     NSCLC harboring activating EGFR kinase domain mutations is a unique subtype 
of NSCLC. NSCLC patients haboring EGFR kinase domain mutations respond well to 
EGFR TKI. However, the emergence of acquired resistance to EGFR TKI greatly limits 
the efficiency of targeted therapy (24). 
     Besides the well-established resistant mechanisms including EGFR T790M 
secondary mutation, and MET amplification mutation, 30 percent of the resistant 
mechanisms remain elusive. Among these unknown resistant mechanisms, about half of 
these resistant NSCLC present an evidence of EMT (45). However, it remains unclear 
which components of EMT directly contribute to the EGFR TKI resistance. Based on the 
mechanisms for known EGFR TKI acquired resistance, we hypothesized that EMT 
program associates with the upregulation of the novel cellular signaling mechanisms that 
the cell can depend on when EGFR activity is inhibited by EGFR TKI. 
      In order to study EGFR TKI resitant mechanisms in EGFR mutant NSCLC cells 
with mesenchymal phenotype, we induced mesenchymal phenotype in HCC827 cells by 
knocking down CDH1. We also made mesenchymal and EGFR TKI resistant HCC827 
cells by stably expressing shRNA against EGFR. It has been reported that AXL is 
overexpressed in mutant EGFR NSCLC cells with mesenchymal phenotype, therefore 
AXL has been considered as a potential candidate to confer resistance to EGFR TKI 
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through ‘receptor tyrosine kinase swith’ (74). In our study we observed the 
overexpression of AXL in EGFR TKI resistant HCC827 shEGFR cells and HCC827 
shCDH1 cells. Furthermore, our experimental results show that AXL phosphorylation is 
dependent on EGFR activity (Figure 4) as inhibition of EGFR with gefitinib 
dephosphorylated not only EGFR but also AXL. The results suggest that AXL activity 
cannot compensate the loss of EGFR activity in our mesenchymal HCC827 shEGFR 
and HCC827 shCDH1 cells. In addition, inhibition of AXL activity using XL-184 or 
depletion of AXL using siRNA did not compromise cell viability or restore their gefitinib 
sensitivity in HCC827 shEGFR and HCC827 shCDH1 clles (Figure 2,5). Our data 
suggests that AXL is less likely to confer resistance to EGFR TKI in HCC827 cells with 
mesenchymal phenotype. We speculated if overexpression of AXL is a biomarker of 
mesenchymal phenotype rather than an oncogenic driver that replaces mutant EGFR. 
In order to identify oncogenic driver for mesenchymal EGFR mutant HCC827 
cells, Dr. Shimamura performed comparative marker selection (CMS) on differential 
gene expression data for HCC827 shEGFR, HCC827 shCDH1 and HCC827 cells 
chronically exposed to TGF-β. G-protein coupled receptor- CXCR7 is significantly 
upregulated in mesenchymal-like HCC827 cells including HCC827 shEGFR, HCC827 
shCDH1 and HCC827 cells chronically exposed to TGF-β (Figure 6). The subsequent 
analysis of mRNA expression and Western blot confirmed the upregulation of CXCR7 in 
the mesenchymal-like HCC827 cells (Figure 7). Of note, our collaborative laboratory at 
Dana-Farber Cancer Institue generated genetically engineered mouse model haboring 
EGFR kinase domain mutant NSCLC tumor and demonstrated that the induction of the 
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mutant EGFR in type II clara cells induce lung adenocarcinoma. In the model, 
adenocarcinoma with acquired resistance to EGFR TKI was observed upon 12 weeks of 
continuous EGFR TKI treatment. Histological analyses of the resistant tumors showed a 
significant upregulation of CXCR7 expression and a significant upregulation of canonical 
mesenchymal markers (data not shown). Collective evidence lead us to further explore 
the role of CXCR7 in EGFR mutant EGFR TKI resistant NSCLC cells. 
The role of CXCR7 with respect to EGFR TKI resistance in EGFR mutant NSCLC 
cells has never been reported. In order to establish the relationship between CXCR7 and 
EGFR TKI resistance, we established an in vitro model that ectopically express V5- 
tagged CXCR7 in EGFR mutant HCC827 cells. We observed that ectopic CXCR7 
overexpression attenuates EGFR TKI sensitivity in HCC827 cells (Figure 12, 13, 14). In 
addition, we observed that AKT phosphorrylation was maintained after acute EGFR 
inhibition by gefitinib treatment in HCC827 CXCR7 cells (Figure 14). Similarly, EGFR 
inhibition did not attenuate AKT phosphorylation in HCC827 CDH1 cells with 
mesenchymal phenotype (Figure 1C). In NSCLC, AKT (S473) phosphorylation serves as 
a biomarker of PI3K pathway activity (28, 29). A considerable number of literature has 
sugguested that CXCR7 activates PI3K pathway through beta-arrestin (84, 95). To our 
surprise, CXCR7 is sufficient to upregulate canonical mesenchymal markers and to 
downregulate epithelial markers(Figure 10, 11). Importantly, depletion of the ectopically 
expressed CXCR7 in HCC827 cells (HCC827 CXCR7-V5) resensitized the cells to 
EGFR TKIs and partially restored epithelial phenotype (Figure 15, 16). The experiment 
confirmed the notion that the ectopically expressed CXCR7 is responsible for the EGFR 
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TKI resistance in HCC827 cells. We observed that CXCR7 depletion- induced a partial 
phenotype revision in HCC827 CXCR7-V5 cells may suggest that CXCR7 induced 
mesenchymal-like cells may activate varieties of autocrine signaling loops that may be 
maintained even after CXCR7 is depleted. The activation of EMT programs involves a 
series of transitions and a spectrum of multiple intermediated states lying between these 
two endpoints (107). The epigenetic regulations of EMT describe the mechanisms that 
impose cellular phenotype with covalent modification of DNA, specially the methylation 
of certain DNA residues, as well as the gain of repressive histone modifications that form 
DNA-associated nucleosomes (107). Therefore, it is possible that the reversibility of 
EMT process requires comprehensive reprogramming of gene expression even though 
the protein that initiates mesnchymal transition is depleted. These evidence may explain 
why depletion of CXCR7 would not completely reverse the process of EMT. 
While overexpression of CXCR7 in HCC827 cells was sufficient to promote EMT 
and to confer EGFR TKI resistance, it remains elusive if ligand stimulation is involved in 
the process. In general, the activation of CXCR7 requires the presence of its ligands 
SDF-1α/ CXCL12 or ITAC/CXCL11 (82). Therefore it is speculated if CXCR7 can be self 
activated without the presence of appropriate ligand if it is sufficiently overexpressed. 
Alternatively, it is possible that ectopic expression of CXCR7 promotes the expression of 
CXCR7 ligand to establish autocrine loop. Nontheless, further investigations to elucidate 
CXCR7 activation mechanisms are necessary.  
Although serval reports have shown that G protein coupled receptor promotes 
EMT, there is no report demonstrating that CXCR7 promotes EMT and EGFR TKI 
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resistance. Our observations may suggest a novel link between chemokine receptor 
CXCR7 and EMT. However, the mechanisms by which CXCR7 induces EMT remain 
elusive. Additionally, we observed CXCR7 induced upregulation of EMT transcription 
factor Twist and Snail in H1975 cells (Figure 11) but not in HCC827 cells (data not 
shown) which indicates that the mechanisms by which CXCR7 induces EMT may be cell 
lineage specific. 
Interestingly, we observed upregulation and phophorylation of AXL in HCC827 
CXCR7-V5 cells (data not shown). However, in consistent with what we observed in 
HCC827 shEGFR and HCC827 shCDH1 cells, gefitinib treatment of HCC827 CXCR7-
V5 cells resulted in decreased AXL phosphorylation and AXL inhibition or depletion by 
siRNA did not restore gefitinib sensitivity in the cells (data not shown). This observation 
suggests that AXL upregulation associates with epithelial to mesenchymal transition but 
AXL activity is not sufficient to replace mutant EGFR activity in mutant EGFR mutant 
NSCLC with mesenchymal phenotype. 
The potential problem of our system with ectopic CXCR7-V5 overexpression in 
HCC827 cells is that we did not confirm if CXCR7 is activated. Since CXCR7 is activated 
by assocaition with β-arrestin, future studies with co-immunoprecipitation or Spell FRET 
(FRET) is required to test if CXCR7 interacts with β-arrestin in HCC827 CXCR7-V5 cells. 
Futher investigation revealed that HCC827 shCDH1 overexpress CXCR7 (Figure 
7) while 42 major RTKs were not phosphorylated (Figure 3). Based on the result, we 
hypothesized that CXCR7 activates PI3K pathway in HCC827 shCDH1 cells when they 
are treated with EGFR TKI. In order to determine if CXCR7 is necessary to confer EGFR 
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TKI resistance in HCC827 shCDH1 cells, we knockdown CXCR7 in EGFR TKI resistant 
mesenchymal-like HCC827 shCDH1 cells using CXCR7- specific siRNA and determined 
if we could restore their sensitivity to EGFR TKI in HCC827 shCDH1 cells. Unfortunately, 
we were not able to effectively depleted CXCR7 using siRNA in HCC827 shCDH1 cells 
(data not shown). Considering the possibility that siCXCR7 we purchased were not 
effective to knockdown CXCR7, we also use lentiviral shRNA against CXCR7 in 
HCC827 Snail-V5 cells that ectopically overexpress EMT-inducing transcription factor 
Snail. HCC827 Snail-V5 cells exhibit mesenchymal phenotype and the cells are resistant 
to EGFR TKI. The data suggested that CXCR7 knockdown restored the EGFR TKI 
sensitivity of HCC827 Snail-V5 cell (data not shown). In conclusion, our data suggests 
that CXCR7 is sufficient and necessary to confer EGFR TKI resistance in HCC827 cells.    
Based on the data we have observed, we proposed that chronic EGFR TKI 
treatment in EGFR mutant NSCLC promotes overexpression of CXCR7 and CXCR7 
maintains survival and proliferation pathway when mutant EGFR is unable to activate the 
pathways under the EGFR TKI treatment (Figure 16). 
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Figure 17. A schematic diagram of a proposed mechanism for CXCR7- mediated 
acuqired EGFR TKI resistance in EGFR mutant NSCLC. Our results suggest that 
CXCR7 is overexpressed in EGFR mutant NSCLC with mesenchymal phenotype. The 
activation of CXCR7 augument the mutant EGFR signaling when mutant EGFR receptor 
is inhibited. CXCR7 signaling promotes cell survival, proliferation and mesenchymal 
phenotype in EGFR TKI resistant EGFR mutant NSCLC cells. 
 
In conclusion, we discovered that ectopic CXCR7 expression in EGFR-TKI 
sensitive HCC827 and NCI-H1975 cells confers EGFR TKI resistance and induces the 
mesenchymal phenotype. Taken together, our data suggests that CXCR7 might have its 
potential therapeutic implications for preventing or overcoming EGFR TKI resistance in 
EGFR mutant NSCLC patients with mesenchymal phenotype. Future studies will be 
necessary will be necessary to determine if CXCR7 is an oncogene in NSCLC and the 
mechanisms of CXCR7 upregulation in NSCLC with EGFR TKI resistance. The 
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investigation will provide insights into the developing the therapeutic intervention of 
CXCR7 mediated EGFR TKI resistance in EGFR mutant NSCLC. 
 
 
 
 
 
 
 
      
 
61 
 
REFERENCES 
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 
2014;64(1):9-29. 
2. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: 
An evolving landscape. Mol Cancer Ther 2010;9(7):1931-44. 
3. Rami-Porta R, Chansky K, Goldstraw P. Updated lung cancer staging system. 
Future Oncol 2009;5(10):1545-53. 
4. Non-small cell lung cancer treatment. . Available from: 
http://www.lungcancer.org/find_information/publications/163-
lung_cancer_101/269-non-small_cell_lung_cancer_treatment. 
5. Parikh RB, Kirch RA, Smith TJ, Temel JS. Early specialty palliative care--
translating data in oncology into practice. N Engl J Med 2013;369(24):2347-51. 
6. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-
small cell lung cancer. J Hematol Oncol 2009;2:2,8722-2-2. 
7. Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z. EGFR-targeted therapies 
combined with chemotherapy for treating advanced non-small-cell lung cancer: A 
meta-analysis. Eur J Clin Pharmacol 2011;67(3):235-43. 
8. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat 
Oncol Biol Phys 2004;59(2 Suppl):21-6. 
9. Downward J, Parker P, Waterfield MD. Autophosphorylation sites on the 
epidermal growth factor receptor. Nature 1984;311(5985):483-5. 
10. Pawson T, Gish GD, Nash P. SH2 domains, interaction modules and cellular 
wiring. Trends Cell Biol 2001;11(12):504-11. 
11. Huang H, Li L, Wu C, Schibli D, Colwill K, Ma S, Li C, Roy P, Ho K, Songyang Z, 
Pawson T, Gao Y, Li SS. Defining the specificity space of the human SRC 
homology 2 domain. Mol Cell Proteomics 2008;7(4):768-84. 
62 
 
 
 
12. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted 
inhibitors. Nat Rev Cancer 2005;5(5):341-54. 
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol 
Cell Biol 2001;2(2):127-37. 
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, 
Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, 
Settleman J, Haber DA. Activating mutations in the epidermal growth factor 
receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N 
Engl J Med 2004;350(21):2129-39. 
15. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye 
FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, 
Johnson BE, Meyerson M. EGFR mutations in lung cancer: Correlation with 
clinical response to gefitinib therapy. Science 2004;304(5676):1497-500. 
16. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, 
Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, 
Gazdar AF. Clinical and biological features associated with epidermal growth 
factor receptor gene mutations in lung cancers. J Natl Cancer Inst 
2005;97(5):339-46. 
17. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations 
of the epidermal growth factor receptor gene in lung cancer: Biological and 
clinical implications. Cancer Res 2004;64(24):8919-23. 
18. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor 
mutations in lung cancer. Nat Rev Cancer 2007;7(3):169-81. 
19. Weinstein IB. Cancer. addiction to oncogenes--the achilles heal of cancer. 
Science 2002;297(5578):63-4. 
20. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, Pao W. Induction of 
BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant 
EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4(10):e294. 
21. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced 
killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be 
enhanced by BH3 mimetics. PLoS Med 2007;4(10):1681,89; discussion 1690. 
22. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, 
Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that 
phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-
63 
 
 
 
jun NH2-terminal kinase-dependent pathways cooperate to maintain lung cancer 
cell survival. J Biol Chem 2003;278(26):23630-8. 
23. Faber AC, Wong KK, Engelman JA. Differences underlying EGFR and HER2 
oncogene addiction. Cell Cycle 2010;9(5):851-2. 
24. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor 
mutations in lung cancer. Nat Rev Cancer 2007;7(3):169-81. 
25. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, 
Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by 
inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2(11):e313. 
26. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, 
Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, 
Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, 
Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and 
clinical characterization of epidermal growth factor receptor (EGFR) exon 20 
insertion mutations in lung cancer. Sci Transl Med 2013;5(216):216ra177. 
27. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, Suehisa H, Ouchida M, 
Aoe K, Aoe M, Kiura K, Shimizu N, Date H. Presence of epidermal growth factor 
receptor gene T790M mutation as a minor clone in non-small cell lung cancer. 
Cancer Res 2006;66(16):7854-8. 
28. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (iressa), a 
novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently 
inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 
overexpression. Int J Cancer 2001;94(6):774-82. 
29. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor 
ZD1839 ("iressa") inhibits HER2-driven signaling and suppresses the growth of 
HER2-overexpressing tumor cells. Cancer Res 2001;61(19):7184-8. 
30. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, 
Yano M, Fujii Y. PIK3CA mutation status in japanese lung cancer patients. Lung 
Cancer 2006;54(2):209-15. 
31. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, 
Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton 
M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, 
32. Thomas RK. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung 
cancer by activation of akt and EGFR. Cancer Res 2009;69(8):3256-61. 
64 
 
 
 
33. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I 
mediates resistance to anti-epidermal growth factor receptor therapy in primary 
human glioblastoma cells through continued activation of phosphoinositide 3-
kinase signaling. Cancer Res 2002;62(1):200-7. 
34. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, 
Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-kappaB 
signalling modulate dependence of lung cancers on mutant EGFR. Nature 
2011;471(7339):523-6. 
35. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson 
N, Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity 
of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth 
factor receptor inhibition. Cancer Res 2005;65(20):9455-62. 
36. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano 
R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC. Epithelial 
versus mesenchymal phenotype determines in vitro sensitivity and predicts 
clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11(24 Pt 
1):8686-98. 
37. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, 
Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, 
Girard L, Gazdar AF, Minna JD, Bunn PA Jr. Restoring E-Cadherin expression 
increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer 
cell lines. Cancer Res 2006;66(2):944-50. 
38. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, 
Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of 
non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352(8):786-92. 
39. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson 
M, Eck MJ. The T790M mutation in EGFR kinase causes drug resistance by 
increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105(6):2070-5. 
40. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman 
N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, 
Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET 
amplification leads to gefitinib resistance in lung cancer by activating ERBB3 
signaling. Science 2007;316(5827):1039-43. 
41. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, 
Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, 
Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET 
65 
 
 
 
amplification occurs with or without T790M mutations in EGFR mutant lung 
tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 
2007;104(52):20932-7. 
42. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, 
Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, 
Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of 
lung adenocarcinoma with epidermal growth factor receptor-activating mutations. 
Cancer Res 2008;68(22):9479-87. 
43. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, 
Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-
kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl 
Acad Sci U S A 2005;102(10):3788-93. 
44. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, 
Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson 
BE, Cantley LC, Jänne PA. Allelic dilution obscures detection of a biologically 
significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 
2006;116(10):2695-706. 
45. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, 
Rogers A, Mok T, Sequist L, Lindeman NI, Murphy C, Akhavanfard S, Yeap BY, 
Xiao Y, Capelletti M, Iafrate AJ, Lee C, Christensen JG, Engelman JA, Jänne PA. 
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. 
Cancer Cell 2010;17(1):77-88. 
46. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, 
Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, 
Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, 
Iafrate AJ, Mino-Kenudson M, Engelman JA. Genotypic and histological evolution 
of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 
2011;3(75):75ra26. 
47. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. 
Curr Opin Cell Biol 2003;15(6):740-6. 
48. Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: Essential for 
behavioral but not morphological changes during an epithelium-to-mesenchyme 
transition. J Cell Sci 2005;118(Pt 5):873-87. 
49. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin 
Invest 2009;119(6):1420-8. 
66 
 
 
 
50. Semb H, Christofori G. The tumor-suppressor function of E-cadherin. Am J Hum 
Genet 1998;63(6):1588-93. 
51. Kim K, Lu Z, Hay ED. Direct evidence for a role of beta-catenin/LEF-1 signaling 
pathway in induction of EMT. Cell Biol Int 2002;26(5):463-76. 
52. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-
cadherin promotes metastasis via multiple downstream transcriptional pathways. 
Cancer Res 2008;68(10):3645-54. 
53. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, Mikulits W, 
Beug H, Foisner R. Beta-catenin and TGFbeta signalling cooperate to maintain a 
mesenchymal phenotype after FosER-induced epithelial to mesenchymal 
transition. Oncogene 2004;23(15):2672-80. 
54. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions 
in development and disease. Cell 2009;139(5):871-90. 
55. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging 
axis of evil in the war on cancer. Oncogene 2010;29(34):4741-51. 
56. de Herreros AG, Peiro S, Nassour M, Savagner P. Snail family regulation and 
epithelial mesenchymal transitions in breast cancer progression. J Mammary 
Gland Biol Neoplasia 2010;15(2):135-47. 
57. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, Maehara Y, Yatabe Y, 
Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal 
growth factor receptor-mutant lung cancer cell line with acquired resistance to 
erlotinib. J Thorac Oncol 2011;6(7):1152-61. 
58. Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, 
Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD. 
Bypassing cellular EGF receptor dependence through epithelial-to-
mesenchymal-like transitions. Clin Exp Metastasis 2008;25(6):685-93. 
59. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, 
Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase 
inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 
2008;118(7):2609-19. 
60. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: 
Biologic functions, signaling, and potential therapeutic targeting in human cancer. 
Adv Cancer Res 2008;100:35-83. 
67 
 
 
 
61. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros 
PF, Bartram CR. A novel putative tyrosine kinase receptor with oncogenic 
potential. Oncogene 1991;6(11):2113-20. 
62. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, 
Gies DR, Jones PF, et al. The anticoagulation factor protein S and its relative, 
Gas6, are ligands for the tyro 3/axl family of receptor tyrosine kinases. Cell 
1995;80(4):661-70. 
63. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, Hunt RW, Trail 
G, Clogston C, Toso RJ, et al. Axl receptor tyrosine kinase stimulated by the 
vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 
1995;373(6515):623-6. 
64. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 
3rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from 
primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. 
Mol Cell Biol 1991;11(10):5016-31. 
65. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, 
Bussolino F. Inhibition of vascular endothelial growth factor receptor 2-mediated 
endothelial cell activation by axl tyrosine kinase receptor. Blood 
2005;105(5):1970-6. 
66. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE. 
Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular 
smooth muscle cells. Circ Res 2007;100(4):502-9. 
67. Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK 
mediates cell aggregation by homophilic binding. Mol Cell Biol 1995;15(2):614-
25. 
68. Burchert A, Attar EC, McCloskey P, Fridell YW, Liu ET. Determinants for 
transformation induced by the axl receptor tyrosine kinase. Oncogene 
1998;16(24):3177-87. 
69. Hafizi S, Dahlback B. Signalling and functional diversity within the axl subfamily 
of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17(4):295-304. 
70. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, Andres AC. Estrogen 
dependent expression of the receptor tyrosine kinase axl in normal and 
malignant human breast. Ann Oncol 2001;12(6):819-24. 
68 
 
 
 
71. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. Clinical 
significance of AXL kinase family in gastric cancer. Anticancer Res 
2002;22(2B):1071-8. 
72. Jacob AN, Kalapurakal J, Davidson WR, Kandpal G, Dunson N, Prashar Y, 
Kandpal RP. A receptor tyrosine kinase, UFO/axl, and other genes isolated by a 
modified differential display PCR are overexpressed in metastatic prostatic 
carcinoma cell line DU145. Cancer Detect Prev 1999;23(4):325-32. 
73. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. Expression of 
axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 
2005;7(12):1058-64. 
74. Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez 
H, Maitra A. The axl receptor tyrosine kinase confers an adverse prognostic 
influence in pancreatic cancer and represents a new therapeutic target. Cancer 
Biol Ther 2009;8(7):618-26. 
75. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang 
X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, 
Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, 
Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. 
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung 
cancer. Nat Genet 2012;44(8):852-60. 
76. Linger RM, Keating AK, Earp HS, Graham DK. Taking aim at mer and axl 
receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert 
Opin Ther Targets 2010;14(10):1073-90. 
77. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, 
McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl 
is an essential epithelial-to-mesenchymal transition-induced regulator of breast 
cancer metastasis and patient survival. Proc Natl Acad Sci U S A 
2010;107(3):1124-9. 
78. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: 
Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9(4):265-73. 
79. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson 
KL. AXL induces epithelial-to-mesenchymal transition and regulates the function 
of breast cancer stem cells. Oncogene 2014;33(10):1316-24. 
80. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri 
U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner 
69 
 
 
 
SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, 
Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein 
JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-
mesenchymal transition gene signature predicts resistance to EGFR and PI3K 
inhibitors and identifies axl as a therapeutic target for overcoming EGFR inhibitor 
resistance. Clin Cancer Res 2013;19(1):279-90. 
81. Libert F, Parmentier M, Lefort A, Dumont JE, Vassart G. Complete nucleotide 
sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res 
1990;18(7):1917. 
82. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, 
Arenzana-Seisdedos F, Thelen M, Bachelerie F. The chemokine SDF-1/CXCL12 
binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol 
Chem 2005;280(42):35760-6. 
83. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold 
ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard 
MC, Schall TJ. A novel chemokine receptor for SDF-1 and I-TAC involved in cell 
survival, cell adhesion, and tumor development. J Exp Med 2006;203(9):2201-
13. 
84. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl B, 
Leung H, Groom J, Batten M, Harvey RP, Martínez-A C, Mackay CR, Mackay F. 
Disrupted cardiac development but normal hematopoiesis in mice deficient in the 
second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A 
2007;104(37):14759-64. 
85. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz 
RJ. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor 
CXCR7. Proc Natl Acad Sci U S A 2010;107(2):628-32. 
86. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 
heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein 
signaling. Blood 2009;113(24):6085-93. 
87. Kumar R, Tripathi V, Ahmad M, Nath N, Mir RA, Chauhan SS, Luthra K. CXCR7 
mediated gialpha independent activation of ERK and akt promotes cell survival 
and chemotaxis in T cells. Cell Immunol 2012;272(2):230-41. 
88. Canals M, Scholten DJ, de Munnik S, Han MK, Smit MJ, Leurs R. Ubiquitination 
of CXCR7 controls receptor trafficking. PLoS One 2012;7(3):e34192. 
70 
 
 
 
89. Graham GJ. D6 and the atypical chemokine receptor family: Novel regulators of 
immune and inflammatory processes. Eur J Immunol 2009;39(2):342-51. 
90. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer 
CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ. CXCR7 (RDC1) 
promotes breast and lung tumor growth in vivo and is expressed on tumor-
associated vasculature. Proc Natl Acad Sci U S A 2007;104(40):15735-40. 
91. Boldajipour B, Mahabaleshwar H, Kardash E, Reichman-Fried M, Blaser H, 
Minina S, Wilson D, Xu Q, Raz E. Control of chemokine-guided cell migration by 
ligand sequestration. Cell 2008;132(3):463-73. 
92. Raggo C, Ruhl R, McAllister S, Koon H, Dezube BJ, Früh K, Moses AV. Novel 
cellular genes essential for transformation of endothelial cells by kaposi's 
sarcoma-associated herpesvirus. Cancer Res 2005;65(12):5084-95. 
93. Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H, 
Miyahara R. Higher expression of chemokine receptor CXCR7 is linked to early 
and metastatic recurrence in pathological stage I nonsmall cell lung cancer. 
Cancer 2009;115(11):2580-93. 
94. Hou KL, Hao MG, Bo JJ, Wang JH. CXCR7 in tumorigenesis and progression. 
Chin J Cancer 2010;29(4):456-9. 
95. Meijer J, Ogink J, Roos E. Effect of the chemokine receptor CXCR7 on 
proliferation of carcinoma cells in vitro and in vivo. Br J Cancer 2008;99(9):1493-
501. 
96. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R, 
Taichman RS. The role of CXCR7/RDC1 as a chemokine receptor for 
CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283(7):4283-94. 
97. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, Dufault MR, 
Zhang X, Zhang W, Walter-Yohrling J, Rouleau C, Akmaev VR, Wang CJ, Cao 
X, St Martin TB, Roberts BL, Teicher BA, Klinger KW, Stan RV, Lucey B, Carson-
Walter EB, Laterra J, Walter KA. Vascular gene expression in nonneoplastic and 
malignant brain. Am J Pathol 2004;165(2):601-8. 
98. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, 
Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 
2007;67(3):1030-7. 
99. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification 
of tumorigenic prostate cancer stem cells. Cancer Res 2005;65(23):10946-51. 
71 
 
 
 
100. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, 
Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with 
cancer stem cell properties in head and neck squamous cell carcinoma. Proc 
Natl Acad Sci U S A 2007;104(3):973-8. 
101. Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes 
Chromosomes Cancer 2002;34(3):255-68. 
102. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal 
transition. Cell Res 2009;19(2):156-72. 
103. Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, 
Minegishi Y, Kubota K, Gemma A. MiR-134/487b/655 cluster regulates TGF-
beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib 
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther 
2014;13(2):444-53. 
104. Xue TC, Chen RX, Han D, Chen J, Xue Q, Gao DM, Sun RX, Tang ZY, Ye SL. 
Down-regulation of CXCR7 inhibits the growth and lung metastasis of human 
hepatocellular carcinoma cells with highly metastatic potential. Exp Ther Med 
2012;3(1):117-23. 
105. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. 
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. 
lesson from an uncleavable mutant. J Biol Chem 1998;273(50):33533-9. 
106. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, 
McDonald DM. VEGF and c-met blockade amplify angiogenesis inhibition in 
pancreatic islet cancer. Cancer Res 2011;71(14):4758-68. 
107. Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of 
development and tumor metastasis. Dev Cell 2008;14(6):818-29. 
108. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in 
cancer. Nat Med 2013;19(11):1438-49. 
  
72 
 
VITA 
      Yandi Gao was born in Qingdao, China, on October 28, 1987. She received 
Bachelor of Pharmaceutical Science degree from Henan University of Chinese 
Traditional Medicine (Zhengzhou, China) in June 2010. 
      In August of 2011, Yandi joined the department of Molecular Pharmacology 
&Therapeutics at Loyola University Chicago (Maywood, IL). She joined the laboratory 
of Dr. Takeshi Shimamura in 2012 where she studied EGFR mutant non-small cell 
lung cancer with resistant to EGFR TKI and mesenchymal phenotype. 
      After finishing her M.S., Yandi plans to continue her research in 
pharmaceutical company or in other cancer institute. 
